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 Although a causal relationship between hepatitis C virus (HCV) persistence and 
regulatory T cells (Tregs) has been purported, to date, no one has demonstrated how the 
induction of Tregs occurs. The central question of this dissertation was to address if HCV 
exploits known CD4+ T cell suppressive mechanisms to cause persistent infection in 
humans. The central finding of these studies was that naturally occurring viral variants of 
HCV that emerged in a major histocompatibility complex class II epitope of the non-
structural-3 protein were acting as altered peptide ligands possibly leading to the 
differentiation of HCV specific CD4+ effector T cells into Tregs. To our knowledge, this 
work is the first demonstration of naturally occurring viral variants inducing Tregs, 
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 The Hepatitis C Virus (HCV) infects approximately 3% of the world’s population 
and is considered a global epidemic by the World Health Organization (WHO) (1). HCV 
is the most prevalent blood borne pathogen in the United States, and carries with it the 
potential risk for liver cirrhosis and hepatocellular carcinoma, making HCV the foremost 
reason for liver transplantation (2).  To date, the only approved treatment available for 
chronic HCV subjects is a combination of pegylated interferon-α (IFN-α) and ribavirin 
therapy, but this method is successful in less than 50% of patients, because the outcome 
is wholly contingent upon the patients’ HCV genotype (3).  This course of treatment, 
however, is not a long-term solution to this global epidemic due to the efficacy, side 
effects, and cost associated with these drugs (4).  Attempts at developing alternative 
therapeutics and vaccines for HCV have been unsuccessful mainly due to the sequence 
heterogeneity of the HCV genome.  This heterogeneity allows HCV to evade the immune 
response, or at least impart a specific tolerance in the patient, thus ensuring the virus’ 
survival in over 80% of infected individuals through mechanisms including, but not 
limited to, viral escape, T cell anergy, and induction of regulatory T cells (Tregs). 
  
HCV Genome 
 HCV, an enveloped positive-stranded RNA virus, is the only member of the genus 
Hepacivirus of the family Flaviviridae.  There are 6 HCV genotypes with more than 100 
subtypes (3). The virus is translated into a 3,000 amino acid poly-protein and cleaved into 
10 proteins by both host and viral proteases (Figure 1.1).  Further, the poly-protein is sub-
divided into structural (core, envelope 1 and 2) and nonstructural (NS2, NS3, NS4A, 
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NS4B, NS5A, and NS5B) proteins, with a p7 protein between these two groups of 
proteins (Figure 1.1) (5). 
 HCV is a hepatotropic virus, but is nonetheless still able to reside in peripheral 
blood mononuclear cells (PBMC), serum, and the central nervous system (6, 7).  HCV 
entry is dependent on numerous receptors such as sulfated heparin sulfate, low-density 
lipoprotein receptor, CD81, scavenger receptor BI, claudin-1, and occludin (8-14).  After 
attaching to the cell surface, the virus is endocytosed via clathrin coated pits into the cell 
(reviewed in (2)). Translation of the viral genome occurs in the cytoplasm and is initiated 
at the internal ribosome entry site (IRES).  HCV is able to form a lipid “web-like” 
membrane for replication and assembly (2).  The structural components of the virus 
important for entry and assembly are flanked by NS2 to NS5b.  NS2 is a protease that 
acts in cis by cleaving between NS2 and NS3 (5).  NS3 has both protease and helicase 
activity.  NS3 is responsible for the cleavage of the other nonstructural proteins with 
NS4A, making this protein essential for viral replication.  The helicase activity of NS3 is 
responsible for unwinding RNA and DNA, but it is still not clear how this process is 
important to viral replication. The function of NS4B and NS5A is likewise unclear.  
However, NS5B has viral RNA-dependent RNA polymerase activity, indicating its 
importance in viral replication.  The focus of this dissertation is on NS3, due to the 
importance of this protease in viral replication. 
 Further, the NS3 genotype used in this dissertation is genotype 1a.  This genotype 
is the most common HCV genotype in the United States (15); its rate of replication is 
extremely high, at approximately 1 x 1012 virions per day (16).  Similar to other RNA 
viruses, HCV lacks RNA-proof reading, leading to a heterogeneous population of the 
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viral genome. The most frequently represented genome is referred to as the wild type 
sequence; the viral variants arising in the viral genome are called quasispecies (17).  The 
majority of circulating virus in chronic HCV patients appears to be the wild type 
population (18-20). The role of these quasispecies or viral variants in HCV pathogenesis 
can possibly range from simple escape from immune detection to deviation of the 
immune system (21, 22). The combination of high viral replication and high error rates 
can be deleterious for viral clearance.  
 
Factors in HCV Clearance 
 HCV clearance is dependent on both a robust innate and adaptive immune 
response.  The host’s first line of defense against HCV is the innate immune response 
when the virus engages pathogen-associated molecular pattern (PAMP) receptors (23).  
During the viral replication a negative strand RNA of HCV is synthesized and it acts as a 
template for the synthesis of additional genomic positive-stranded RNA destined for viral 
progeny.  The double stranded RNA is recognized by the toll-like receptor 3 (TLR3) and 
the retinoic acid-inducible gene I (RIG-I)-receptor, both PAMP receptors, leading to 
transcription and secretion of type-1 IFNs, thereby creating an antiviral state.  The 
process of HCV being largely asymptomatic in the early onset of infection has led to a 
major challenge in studying the innate immune response to HCV; also, having few model 
systems has led to a deficit in knowledge as to how the human immune system is able to 
clear the virus during the acute phase of infection. 
 Although the innate immune system’s role in HCV clearance is not clearly 
defined, in general, the innate immune system is able to initiate or “set the stage” for the 
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adaptive immune response during viral infections.  The adaptive immune response is 
triggered when T cells are activated.  T cell activation occurs when a T cell receptor 
(TCR) binds to cognate or specific peptide bound to major histocompatibility complex 
(MHC) molecules on the surface of antigen presenting cells (APCs) (24).  The 
engagement of the TCR to pMHC is necessary for the activation of CD4+ and CD8+ T 
cells, thereby leading to an effective adaptive immune response against an invading 
pathogen (Figure 1.2) (25). If co-stimulatory molecules associated with T cell activation 
are not activated along with TCR engagement, the T cells can become unresponsive. 
 The recognition of viral epitopes by T cells is critical for the clearance of viruses 
(26).  In the case of HCV infection, clearance of the virus has been found to be dependent 
upon the quality of the CD4+ T cell response in up to 30% of infected individuals (27-
30).  Although CD8+ T cells are responsible for killing virus-infected cells, it is now 
accepted that CD4+ T cells are also critical for HCV clearance (31).  CD4+ T cells help 
direct the adaptive immune response to viral infections by providing help for CD8+ T 
cells, enhancing antigen presentation, and playing a role in B cell maturation.  The most 
direct correlation showing the importance of HCV-specific CD4+ T cells was a study 
demonstrating antibody-depletion of CD4+ T cells from chimpanzees prior to reinfection 
(28).  The depletion of CD4+ T cells resulted in persistent infection, despite the presence 
of memory HCV-specific CD8+ T cells (28). Although this experiment clearly 
demonstrated the importance of CD4+ T cells in HCV clearance, it did not reveal a 
specific role for these cells in viral clearance.  In vitro data using chronic and resolved 
HCV PBMC show an attenuation of or absent of HCV-specific CD4+ T cells in chronic 
subjects, while the T cell responses in resolved subjects were broad and vigorous (32).  
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Although in vitro studies demonstrate a role for CD4+ T cells in HCV clearance, it has 
not been determined how HCV is able to subvert these T cells in the case of viral 
persistence. 
 A major component of an effective immune response against HCV is the breadth 
and magnitude of the HCV-specific CD4+ T cell responses against the HCV NS3 protein 
(21).  Due to the importance of this protein, the focus of this dissertation is on the NS3 
protein.  This protein contains a number of immunogenic epitopes that have been 
identified in both humans and chimpanzees (18, 20, 27, 29, 33-36).  Although there are a 
number of studies that have found an association between the numbers of epitopes 
recognized in resolved vs. chronic subjects (29, 37), the only accepted difference between 
these two groups is the sustainability of the antigen-specific T cell response throughout 
the course of infection in the resolved subjects.   A genetic component that could be 
important for viral clearance is the MHC; these molecules are responsible for presenting 
the epitope or peptide fragment to T cells, leading to the hypothesis that the MHC could 
be a factor in viral clearance.  There are certain MHC class II alleles in humans that have 
an association with clearance, indicating that CD4+ T cells are important in HCV 
clearance (reviewed in (30)). These studies are still incomplete and need further 
investigation. 
 As discussed above, the CD4+ T cell responses are found to be narrow and 
attenuated in chronic HCV subjects. In general, CD4+ T cell responses are phenotypically 
characterized by the type of cytokines secreted along with the expression of certain 
transcription factors when activated.  To date, there are four characterized CD4+ T cell 
subsets. Also, the development of CD4+ T cells is directed by cytokines produced by the 
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innate immune system.  The predominant model for CD4+ T cell responses is the TH1 –
Th2 paradigm (38).  The differentiation of naïve CD4+ T cells to effector/ memory TH1 
cells is important in clearance of intracellular pathogens.  Development of TH1 cells is 
dependent on IFNγ and (interleukin-12) IL-12 and secrete IL-2 and IFNγ (39, 40). The 
development of Th2 cells is dependent on IL-4 and this subset clears parasites by driving 
the humoral immune response and secretes cytokines IL-4, IL-5, IL-10, and IL-13 (41).  
Recently, CD4+ T cells with a suppressive phenotype have been characterized and are 
called Tregs (42). Tregs are able to prevent autoimmunity and immunopathology 
associated with an infection, either through contact mediated mechanisms or secretion of 
IL-10 (43). Treg’s differentiation is dependent on IL-10 and transforming growth factor β 
(TGFβ) (44). The fourth CD4+ T cell subset is TH17 cells.  These cells have a role in 
bacterial clearance and they are differentiated into IL-17A, IL-17F, IL-21, and IL-22 
secreting cells through the cytokines IL-6 and TGFβ, but the role of these cells in HCV 
has not been reported (reviewed in (45)).  Also, a subpopulation of CD4+ T cells is able 
to directly kill virus-infected cells through perforin and granzyme B mechanisms.  
Patients with chronic HCV have been shown to have higher serum levels of IL-10 and 
IL-4, suggestive of either Tregs or TH2 T cells (19, 46).  The induction of TH1 responses 
is related to clearance of the virus (Figure 1.3) (21, 27). 
 Previous work in our laboratory demonstrated a functional induction of IL-10 in 
CD4+ T cells in chronic HCV subjects, indicative of inducible Tregs, as opposed to 
resolved HCV subjects, which secreted TH1 cytokines (21, 30). Furthermore, screening 
for immunodominant epitopes in one chronic HCV subject, using an array of synthetic 
peptides, found a TH1 epitope, NS3358-375, showing a distinct cytokine profile in contrast 
 8 
to the rNS3 protein-stimulated PBMC (47).   In a longitudinal study tracking viral 
variants in a chronic HCV subject, we identified viral variants consistent with selective 
immune pressure (48).  One variant, S370P, was noted to be stable for over 2 years, 
indicating selection and fixation of this HCV viral isolate (22, 48).  Simple escape and 
redirection of the immune response does not explain, however, the maintenance of an 
abundant population of wild type HCV sequences in infected patients, even years into an 
ongoing infection.  The paradox is that viral genomes persist in the presence of T cells, 
which should be able to specifically recognize and help to clear virus-infected cells.  This 
suggests that there may be another level of immunoregulation that is modulated by the 
viral infection (49-53).  Based on these observations, we hypothesize that a population of 
Tregs specifically suppresses the response of the effector T cells to the HCV antigens, 
and this Treg-mediated suppressive activity is induced by naturally occurring viral 
variants that accumulate mutations in an important viral epitope recognized by T cells.  
This suppressive mechanism does not preclude the virus’ ability to evade clearance 
through mechanisms such as escape and T cell exhaustion.  
 
Tregs in HCV Infection  
 Recent studies on HCV have described an increase in Treg markers in cohorts of 
chronically infected patients when compared to resolved and noninfected individuals, 
possibly leading to viral persistence (Figure 1.4) (19, 54-59). Although these studies 
suggest a correlation between numbers of Tregs and HCV clearance, it has not been 
determined if Tregs are induced in an antigen-specific manner, or if they are up regulated 
to inhibit immunopathological damage associated with a chronic infection (Figure 1.4).  
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 There are two main subsets of Tregs:  (I) thymically selected natural Tregs 
(nTreg), which are phenotypically defined as CD4+ CD25hi Foxp3+, and (II) “inducible” 
Tregs, activated in the periphery, termed either Tr1 or Th3, and defined as secreting IL-
10, TGFβ and possibly IL-4 (60, 61).  A variety of markers are available to define Tregs, 
but the most generally accepted marker is the expression of Foxp3 (42).  This expression  
positively correlates with the development of Tregs that have the capacity to suppress the 
in vitro and in vivo proliferation and function of effector T cells (62-66).  Recent  
Studies have found a correlation between α-chain of IL7R (CD127) and Treg cells (67).  
Golden-Mason et al. (68) also found a correlation between CD127 expression and the 
virological outcome of acute HCV, suggesting a relationship between HCV persistence 
and an increase in Tregs.   The mechanism of the induction of Tregs has not been 
delineated and is a major focus of this dissertation. 
 
 Role of Altered Peptide Ligands (APLs) in Viral Infection 
 Single amino acid substitution in the cognate peptide, termed APLs, can elicit a 
gradient of effector function in a specific T cell (Figure 1.2) (69).  One such mechanism 
that HCV may be able to exploit for persistence includes APLs, which have been 
observed within the hypervariable region 1 (HVR1) of HCV (70, 71), and in other 
pathogens, such as, Hepatitis B Virus (HBV) (26, 72), Human Immunodeficiency Virus 
(HIV) (73, 74), and plasmodium falciparium (75). Our previous studies identified and 
tracked viral variants arising in a single HCV chronic individual and further determined 
the effect these variants had on the in vitro immune response (22, 48, 76). Although HCV 
circulates in the host as a quasispecies, it appears that such variation does not lead to viral 
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escape, but rather that some variants are able to suppress the immune response in an 
antigen-specific manner. 
 
 Convergent Suppression 
 Although the induction of Tregs and naturally occurring APLs are used by HCV 
to evade clearance, these adaptations employed by the virus may or may not be part of a 
common mechanism.  The central hypothesis of this dissertation is that HCV has 
implemented the mechanism of APLs to induce Tregs (Figure 1.5).  
 
Preview of Dissertation 
 This dissertation demonstrates a mechanism by which HCV is able to impart 
tolerance to itself and possibly leading to persistence. We demonstrate in vitro induction 
of Tregs capable of suppressing antigen-specific T cell responses. We postulated that 
previously defined viral variants in an immunodominant epitope could be responsible for 
the induction of Tregs based on the cytokine shift and attenuated T cell response (21). 
Furthermore, we demonstrate that chronically infected subjects exhibit significantly 
lower T cell responses in comparison to resolved subjects.  These attenuated T cell 
responses correlated with the induction of the Treg lineage-specific markers in HCV-
specific CD4+ T cells. Our initial findings indicate that variants in at least one epitope of 
HCV NS3 could induce Tregs and attenuate T cell responses in vitro.    
 Testing the specificity of these naturally occurring viral variants, we used T cell 
clones and found that these variants antagonized these T cells.  These results suggested 
that naturally occurring variants within an immunodominant epitope may act as APLs, 
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leading to changes in the quality of T cell responses, which could allow for viral 
persistence. 
 The third part of the thesis is a “convergence” of Treg induction and naturally 
occurring viral variants acting as APLs. The suppression imparted by these variants was 
dependent on both the wild type and variant peptide being present.  This finding sheds 
light on how the wild type population is able to persist in the host as the dominant 
quasispecies, despite being detected by the host. Lastly, one viral variant, S370P, induced  
an up regulation of Foxp3 in MHC class II tetramer wild type positive cells.  These 
results demonstrate a stable viral variant in a chronic HCV subject is able to induce Tregs 
in multiple individuals that are able to respond to an HCV-specific CD4+ T cell epitope.  
These results clearly demonstrate that one mechanism of HCV persistence is through 
naturally occurring APLs that change effector viral clearing CD4+ T cells into Tregs.  
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Figure 1.1.  Schematic of the Hepatitis C Virus (HCV) viral life cycle.  The 
nonstructural-3 (NS3) protein is a protease and helicase that is critical for both viral 






Figure 1.2.  Altered peptide ligands (APLs) lead to partial activation or 
nonresponsiveness in CD4+ T cells.  The immunogenic peptide (black) is able to fully 
activate the antigen-specific CD4+ T cells when the immunogenic peptide loaded onto the 
major histocompatibility complex (MHC) is presented to the T cell.  APLs (red) are 
defined as amino acid changes in the immunogenic peptide that are able to bind to the 
same T cell receptor (TCR) as the immunogenic peptide, leading to partial activation or 





Figure 1.3.  Resolved subject’s CD4+ T cell response to NS3 protein in comparison to 
chronic patients CD4+ T cell response to NS3 protein.  Resolved HCV subjects have a 
CD4+ TH1 T cell response to HCV protein NS3.  Chronic HCV patients have an 








Figure 1.4.  Regulatory T cell (Treg) frequency is higher in chronically infected patients 
when compared to resolved and noninfected subjects.  A.  Tregs are critical for 
maintaining homeostasis of the immune system.  B.  Chronically infected HCV patients 







Figure 1.5.  Convergent suppression.  The hypothesis of the dissertation that HCV is able 
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 Regulatory T cell markers are increased in chronically infected individuals with 
the hepatitis C virus (HCV), but to date, the induction and maintenance of Tregs in HCV 
infection has not been clearly defined. In this study, we demonstrate that naturally 
occurring viral variants suppress T cell responses to cognate NS3358-375 in an antigen 
specific manner.  Of four archetypal variants, S370P induced regulatory T cell markers in 
comparison to NS3358-375 stimulated CD4 T cells.  Further, the addition of variant specific 
CD4 T cells back into a polyclonal culture in a dose dependent manner inhibited the T 
cell response.  These results suggest that HCV is able to induce antigen-specific 
regulatory T cells to suppress the antiviral T cell response in an antigen specific manner, 
thus contributing to a niche within the host that could be conducive to HCV persistence. 
 
Introduction  
 Hepatitis C Virus (HCV) may evade the immune response or impart a specific 
tolerance to itself to ensure its survival in over 80% of infected individuals through 
mechanisms such as, but not excusive to, viral escape, T cell anergy and induction of 
regulatory T cells (Treg).   
 Recent studies on hepatitis C virus (HCV) have described an increase in Treg 
markers in cohorts of chronically infected patients when compared to resolved and 
noninfected individuals, possibly leading to viral persistence (1-7). Although these 
studies suggest a correlation between Treg cell numbers and HCV clearance, it has not 
been determined if Tregs are induced in an antigen-specific manner, or upregulated to 
inhibit immunopathological damage associated with a chronic infection.  
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 There are two main subsets of Tregs:  (I) thymically selected natural Tregs 
(nTreg) which are phenotypically defined as CD4+ CD25hi Foxp3+ and (II) “inducible” 
Treg cells, activated in the periphery, termed either Tr1 or Th3 defined as secreting IL-
10, TGFβ and possibly IL-4 (8, 9).  A variety of markers are available to define Tregs, 
but the most generally accepted marker is the expression of Forkhead Box P3 (Foxp3).  
This expression positively correlates with the development of Treg cells that have the 
capacity to suppress the in vitro and in vivo proliferation and function of effector T cells 
(10-14).  Recent studies have found a correlation between α-chain of IL7R (CD127) and 
Treg cells (15).  Golden-Mason et al. also found a correlation between CD127 expression 
and the virological outcome of acute HCV suggesting a relationship between HCV 
persistence and an increase in Treg cells (16). 
 Previous work in our laboratory demonstrated a functional induction of IL-10 in 
CD4 T cells in chronic HCV subjects, indicative of inducible Treg cells, as opposed to 
resolved HCV subjects which secreted IL-2 and IFNγ (17, 18). Further, screening for 
immunodominant epitopes in one chronic HCV subject using an array of synthetic 
peptides, found an IFNγ and IL-2 producing epitope NS3358-375 showing a distinct 
cytokine profile in contrast to the rNS3 protein stimulated PBMC (19).   In a longitudinal 
study, tracking viral variants in a chronic HCV subject, we identified viral variants 
consistent with selective immune pressure (20).  One variant, S370P, was noted to be 
stable for over 2 years indicating selection and fixation of this HCV viral isolate (20, 21).  
Simple escape and redirection of the immune response does not explain, however, the 
maintenance of an abundant population of wild type HCV sequences in infected patient’s 
even years into an ongoing infection.  This paradox is that viral genomes persist in the 
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presence of T cells, which should be able to specifically recognize, and help to clear virus 
infected cells and suggests there may be another level of immunoregulation that is 
modulated by the viral infection (22-26).  Based on these observations, we hypothesize 
that a Treg population specifically suppresses the response of the effector T cells to the 
HCV antigens, and this Treg-mediated suppressive activity is induced by naturally 
occurring viral variants that accumulate mutations in an important viral epitope 
recognized by helper T cells. 
 In the present study, we evaluated the role of naturally occurring viral variants in 
the suppression of T cell responses to cognate NS3358-375 in vitro.  Of four archetypal 
variants, the S370P variant induced regulatory T cell markers in comparison to NS3358-375 
stimulated CD4 T cells.  Further, adding variant specific CD4 T cells back into a 
polyclonal culture, in a dose dependent manner, inhibited the T cell response to cognate 
NS3358-375.  These results suggest that HCV may be able to induce regulatory T cells to 
suppress the antiviral T cell response in an antigen specific manner; potentially creating a 
niche within the host that could be conducive to HCV persistence. 
 
Materials and Methods 
Patients 
 Blood was collected in acid citrate dextrose and processed for PBMC isolation 
over Lymphocyte Separation Medium and preserved in liquid nitrogen, as previously 
described (27).  DNA was isolated from whole blood and sent for HLA typing at the 
University of Utah (Table 2.1) and the lymphocytes were incubated with various 
concentrations of rNS3 to test for T cell responses. Quantitative RT-PCR and HCV 
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genotyping on all serum samples were sent to ARUP laboratories (Salt Lake City, UT).  
All chronic HCV subjects used in this study are genotype 1a (Table 2.1).  If the subjects 
had no detectable viral load, the samples were screened for HCV antibodies by 
recombinant immunoblot assay (RIBA) carried out at ARUP laboratories.  These studies 
have been reviewed and approved by University of Utah Institutional Review Board and 
the Medical College of Wisconsin Institutional Review Board. 
 
 Cell Culture and Media 
 Culture of PBMC was in RPMI 1640 tissue culture medium (BioWhittaker, 
Walkersville, ME) supplemented with 25 mM HEPES, 2 mM L-glutamine, 100 U/ml 
penicillin, 100 µg/ml streptomycin, 1 mM sodium pyruvate, 5 µg/ml gentamycin (all 
from Mediatech Cellgro, Herndon, VA), 10 U/ml heparin sodium (Fisher Scientific, 
Pittsburgh, PA) and 10% pure human serum (Atlanta Biologicals, Lawrenceville, GA).  
Cells were cultured in a 37ºC, 5% CO2 incubator. 
 
 Synthetic Peptides and Protein 
 In vitro PBMC were stimulated with synthetic peptides representing one human 
leukocyte antigen DR15 (HLA-DR15) restricted epitope surrounding HCV NS3 amino 
acids 358-375 (a.a. 1384-1401 of the HCV polyprotein).  The three single amino acid 
variants were identified in a chronic HCV patient (P.B3019), and recombinant 
nonstructural protein 3 (rNS3) protein was purified as previously described (17, 28).  
Recombinant H3 (A/Phillipines/1992) and H5 (A/Vietnam/2004) were obtained from 
Protein Sciences.  Peptides were synthesized using Fmoc chemistry and HPLC purified, 
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dissolved in a small amount of DMSO, and then adjusted to 1 mg/ml stock solutions in 
RPMI 1640.  Peptide sequences were as follows: wild type 358-375, 
VIKGGRHLIFCHSKKKCD; variant H369R, VIKGGRHLIFCRSKKKCD; variant 
S370P, VIKGGRHLIFCHPKKKCD; variant K371E, VIKGGRHLIFCHSEKKCD. 
 
 T Cell Proliferation Assay 
 To measure proliferative responses of PBMC following stimulation with wild 
type peptide NS3358-375 and several variants, 1 x 105 PBMC were plated in round-bottom 
96-(29)incubated at 37ºC, 5% CO2 for either 4 or 6 days, as indicated, pulsed overnight 
with 1 µCi/well of titrated thymidine (3H-TdR), and harvested onto glass fiber filters for 
measurement of radiolabel incorporation by gas scintillation spectroscopy.  Results are 
presented as the mean ± SEM of at least triplicate cultures (typically 6 wells/sample were 
analyzed), and samples were compared using Student’s unpaired t-test.  Data were 
considered significant at P <0.05. Proliferation data was transformed using a previously 
described algorithm:  log10Δcpm=log10 [Xexp- Xexp] (29). 
 
 Foxp3 Staining 
 PBMC were analyzed by flow cytometry to evaluate the frequency of Foxp3 in an 
expanding CD4+ T cell population when stimulated with various antigens in both HCV 
chronic and resolved subjects. Carboxyfluorescein succinimidyl ester (CFSE) staining 
protocol was adapted from Quah et al.  (30).  Briefly, 0.5µM CFSE was added to PBMC 
in complete media + 10% PHS for 5 min. at 37°C, washed 3 times, and stimulated with 
the appropriate antigen(s) for 7 days.   Cultures were then stained with CD4-Pacific Blue, 
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CD8-Amcyan, CD25-APC, and CD127-percp-cy5.5 (BD Pharmingen, San Diego, CA) 
for 20 min. at 4˚C and then washed 2x with stain buffer (BD Pharmingen, San Diego, 
CA).  Using eBioscience Foxp3 staining kit, the cells were fixed and permeabilized for 
1hr at 4˚C, washed 2x in permeabilization buffer.  Normal rat serum was added 
(2µl/100µl) for 15 min. and then stained with Foxp3-PE (eBioscience, San Diego, CA) 
for 1hr at 4˚C, washed 2x with stain buffer and analyzed on a BD FACS Canto II.  To 
account for fluorescence spill over and nonspecific staining, we performed fluorescence-
minus-one (FMO) with isotype control.  More specifically, FMO controls contain all of 
the antibody conjugates used in the experiment except one, with the addition of the 
appropriate isotype control of the fluorochrome initially excluded.  This was performed 
for each fluorochrome and each unique culture condition. For PH1127, the addition of 
IL-10 was added 3 hrs. after the appropriate antigen was added to culture at 2ng/ml.  
Results were compared using Student’s t-test.  Flow cytometry data analysis was 
performed using Flow Jo software (Tree Star). 
 
 Magnetic Cell Sorting 
 To deplete CD4+CD25+ Treg cells from the PBMC, magnetically labeled 
microbeads were used and selected for using an autoMACS Separator (Miltenyl Biotec, 
Auburn, CA).  First, non-CD4+ cells were labeled by incubation with a cocktail of biotin-
labeled anti-human antibodies against CD8, CD14, CD16, CD19, CD36, CD56, CD123, 
TCRγ/δ, and glycophorin A, followed by addition of anti-biotin microbeads, as 
recommended by the manufacturer of the CD4+CD25+ regulatory T cell isolation kit 
(Miltenyi Biotec).  The non-CD4+ cells were then depleted with the autoMACS separator, 
 32 
resuspended in culture media, and set aside.  CD25 microbeads were added to the 
remaining CD4+ cell pool, and positively selected with the autoMACS.  The resulting 
CD25-depleted CD4+ cells were pooled with the non-CD4+ cells, and cultured with 
peptides as described above for proliferation assays. 
 
 Tetramer Staining 
 All tetramers were obtained from the NIH tetramer facility at Emory University. 
PBMC were stained immediately following thawing and washing.  The CD4+ T cells 
specific for NS3358 were amplified by stimulating PBMC from PB3019 with 1µM of 
cognate peptide and incubating the cells at 37ºC, 5% CO2 for 7 days. The cells were then 
sorted at the University of Utah cell sorting core facility. PBMC were stained with CD4-
APC (BD bioscience) and sorted under sterile conditions by gating on CD4+ CFSElow 
cells.  The sorted cells were expanded with CD3/CD28 Dynal beads (Invitrogen) and 
10U/ml of rIL-2 (BD Bioscience) at 37ºC, 5% CO2.  Prior to staining with either wild 
type 358-375- Phycoerythrin (PE), or variant H369R-Allophycocyanin (APC); variant 
S370P-APC; variant K371E –APC tetramers, the CD3/CD28 beads were magnetically 
removed from the cultures and the cells were stained with 2µg/ml of tetramer at 37ºC for 
1hr in complete media plus 10%PHS.  Extracellular surface staining was performed by 
adding 7-AAD cell viability probe, CD4-pacific blue (BD bioscience), CD3-Amcyan 
(BD bioscience), CD8-FITC (eBioscience).  Negative controls consisted of staining cells 
with nonspecific peptide, CLIP-DR15 tetramer, labeled with either –PE label or –APC, 
respectively, which were performed with each experiment and noninfected individuals.  
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Tetramer Depletion and Add Back Assays 
 Tetramer staining (10µg/ml) with the wild type 358-375- Phycoerythrin (PE), 
variant H369R-Allophycocyanin (APC); variant S370P-APC; variant K371E –APC were 
incubated with PBMC (1 X 106 cells/50µl) in a 96 round well bottom plate for 90 min. at 
RT temperature in the dark.   The cells were washed, and MACS beads specific for either 
anti-APC or anti-PE were incubated with their respective tetramer for 15 min. at 4°C.  
The Cells were washed, and then applied to MS MACS column and tetramer depleted.  
Tetramer positive cells were then collected and washed.  Next, the cells were washed 2x 
in complete media + 10%PHS and then stimulated with the appropriate antigens.  In the 
appropriate cultures tetramer positive cells were added to cultures in a dose dependent 
manner based on volume.   A CLIP loaded tetramer for both PE and APC fluorochromes 
used as a control for nonspecific staining. 
 
Results 
Foxp3 Expression in Chronic and Resolved HCV Subjects 
 To compare chronic (n=8) and resolved (n=8) HCV subjects’ T cell responses to 
rNS3, we measured recall responses in vitro (Table 2.1 and Figure 2.1). Responders were 
considered as those giving a response greater than 2 STDs above Xbkg.  Figure 2.1 shows 
the medium background subtracted from the triplicate response to give a Δcpm value 
plotted on a log scale, described in methods. As controls, we included H3 (3µg/ml), H5 
(3µg/ml), and PHA (2µg/ml) (Figure 2.1).  Each subject responded to PHA and there was 
no statistically significant difference in the T cell response for any of the control antigens.  
However, rNS3 induced T cell proliferation in chronic subjects (3.1 SEM ±0.17) was 
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significantly attenuated (p<0.05) compared to resolved subjects (4.01 SEM ±0.15).  
Similarly, flow cytometric analysis of proliferating T cells stained with CFSE (Figure 
2.2) reveals a significantly (p<0.05) attenuated CD4+ T cell response in chronic HCV 
subjects (0.42 SEM ±0.15) (n=7) when compared to the resolved subjects (2.9 SEM 
±0.68) (n=9) (Figure 2.2, Table 2.2).  Although the CD8+ T cell response was not 
statistically significantly lower in the chronic compared to resolved T cell subjects, a 
trend towards lower CD8+ T cell response was evident in the chronic (1.8 SEM ±1.8) 
compared to resolved (3.1±0.7) (Figure 2.2, Table 2.2).   
 To determine if CD127 (IL-7Rα) correlated with chronicity as determined by 
other laboratories (16), we used flow cytometric analyses to analyze the CD127 
expression on both CD4+ and CD8+ T cells in chronic (n=7), resolved (n=10), and 
noninfected (NI) (n=5) on day 7 post-stimulation antigen stimulation (Table 2.3). Further, 
the up regulation of CD127 on CD4+ T cells has been shown to inversely correlate with 
Tregs in humans and the negative selection of CD127 can be used as an accurate extra-
cellular biomarker of Tregs as opposed to CD25 (15).  The noninfected subjects had a 
significantly (p<0.05) lower expression of CD127- (26 SEM ± 4.1) cells in comparison to 
resolved (40 SEM ±2.8) and chronic (62.2 SEM ±4.2) subjects (Table 2.3) and the levels 
remained relatively consistent regardless of antigen stimulation.   To test if HCV was 
able to induce antigen-specific Tregs, we analyzed CFSE dilution assays staining for 
CD4+ CD127- CFSElow cells at 7 days post-stimulation (Figure 2.3A). Chronic HCV 
subjects (16.6 SEM ±5.2) had a significantly higher expression of Foxp3 in antigen 
specific CD4 T cells that were CD127- (0 SEM ±3.7) or negative controls stimulated with 
H3 (0 SEM ±2.4) (Figure 2.3B, Table 2.4). These results suggest antigen stimulation with 
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rNS3 causes expansion of regulatory T cells at a higher frequency in chronic HCV 
subjects compared to resolved HCV subjects. 
 
 Synthetic Peptide-Mix Experiments 
  Previous work in our laboratory identified Th1 epitopes in a single HCV chronic 
subject and further characterized the viral-variants that arose in one of the Th1 epitopes 
identified, NS3358-375 (21, 31).  Further, these variants were found not only to escape 
immune detection but were able to shift the cytokine profile from a Th1 cytokine pattern, 
which is correlated with viral clearance, to either a Th2 or Treg viral persisting response, 
respectively (21, 31). Because variants and “wild type” viruses exist together in the 
circulation, we attempted to simulate in vivo conditions by using what we have termed 
peptide-mixing experiments in cell-culture assays.  Extensive work was performed using 
P.B3019 PBMC to test the effect of various peptide concentrations and kinetics that each 
of the variants had on the cognate T cell response (data not shown). It should be noted 
that our approach is very similar to previously described antagonism assays, with the 
exception being that we used polyclonal PBMC instead of T cell clones (32).    Our 
preliminary experiments showed that the proliferative response of PBMC preincubated 
with 1µM of variant peptide 3 hrs. prior to the addition of 1µM NS3358-375 peptide was 
inhibited (data not shown), which is consistent with an antagonism model. Further, if 
NS3358-375 peptide was added either before or at the same time as the variant peptide, 
there was no effect on NS3358-375 T cell proliferation (data not shown).  Therefore, in 
subsequent experiments, variant peptide remained after the addition of the NS3358-375 
peptide and cultures were incubated at 37°C at 5% CO2 for either 5 or 7 days then pulsed 
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with 3H-Thymidine for the last 16-18 hrs. Cultures incubated with single peptide variants 
alone failed to stimulate as well as the wild type NS3358-375 peptide (Figure 2.4).  Further, 
peptide-mix cultures (variant(s) + wild type) showed reduced levels of proliferation 
relative to those with NS3358-375 peptide alone (Figure 2.4). 
 
Flow Cytometric Analysis of Inducible Tregs 
 To determine if variant S370P was able to induce Tregs in an antigen specific 
manner, we stimulated P.B3019 PBMC with the indicated antigens, incubated the cells 
for 7 days and analyzed the phenotype of proliferating cells in a CFSE dilution assay 
(Figure 2.3A). The induction of Foxp3 by variants H369R and K371E was not 
significantly higher in comparison to NS3358 peptide stimulated cultures but S370P 
induced a large population of Foxp3+ cells (Figure 2.5A). Multiple experiments were 
performed using S370P because S370P was the only variant that was stable for over 2 
years in PB3019 (Figure 2.5B). PBMC from PB3019 (n=3) increased Foxp3 expression 
(p<0.05) when stimulated with S370P (x= 81.8%) (Figure 2.5B) in comparison to 
unstimulated culture (x= 55.73%) (Figure 2.5B). 
 
 CD4+CD25+ Treg Depletion 
 To determine if naturally occurring variants inhibit T cell proliferation, we used 
commercially available CD4+CD25+ regulatory T cell isolation kit to deplete CD4+CD25+ 
T cells from a PBMC pool prior to stimulation with the NS3358-375 and variant peptides 
(Figure 2.6).  Depletion of CD4+CD25+ Tregs enhanced the proliferation of T cells in 
response to NS3358-375 peptide (Figure 2.6, gray vs. black stripped bars, respectively).  
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Furthermore, stimulation with the K371E variant alone in cultures depleted of 
CD4+CD25+ Treg cells, led to an increase in the proliferation level, suggesting that at 
least one mechanism by which the peptide variants suppress effector T cell responses is 
through the induction of Tregs. 
 
 MHC Class II Tetramer Staining Using Multiple HCV Subjects 
 To determine if DR15 MHC class II tetramers loaded with NS3358-375, or the 
variant peptides H369R, S370P, and K371E, were able to bind to CD4+ T cells, PBMC 
from multiple HCV subjects were stained for antigen-specific T cells (Figure 2.7). 
P.1163, a noninfected DR15 subject (Table 2.1), was used as a control.  Also, DR15 
CLIP –PE and –APC tetramers were used as controls in each experiment (Figure 2.7, 
bottom two rows).  Both P.B3019 (chronic infection) and JVP008 (resolved infection) 
had detectable DR15-restriced CD4+ T cells with varying avidities for the tetramers 
(Figure 2.7). Finding HCV-specific T cells in more than one HCV subject suggests that 
this is not an idiosyncratic phenomenon although larger numbers of patients need to be 
studied in order to determine whether our results reflect a more general observation. 
 
 MHC Class II Tetramer Depletion Assays 
 To test the specificity of variant-induced suppression, PBMC were stained with 
variant-loaded tetramers and magnetic beads were used to remove tetramer-positive T 
cells; such depleted PBMC cultures were subsequently stimulated with peptides as 
indicated (Figure 2.8 A-D).  Both H369R and K371E tetramer-depleted cultures 
responded better to NS3358-375 peptide in comparison to the nondepleted cultures (Figure 
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2.8 A, C).  Although S370P tetramer depleted cultures did not have a statistically 
significantly higher T cell response in comparison to nondepleted cultures, S370P-
depleted cultures consistently showed an enhanced T cell response to NS3358-375 (Figure 
2.8B).  Adding back tetramer positive cells to depleted cultures restored suppression 
(Figures 2.8A-C, black bars). Using a nonspecific control tetramer showed no effect on T 
cell responses to the NS3358-375 peptide (Figure 2.8D).  The results indicate that tetramer 
depletion of variant-specific T cells enhances T cell proliferative response to the NS3358-
375 cognate peptide in an antigen specific manner. 
 
MHC Class II Tetramer Add-Back Assays 
 To address the potency of variant-specific T cells to suppress the cognate T cell 
response, we added variant tetramer positive cells back into PBMC culture stimulated 
with NS3358-375 peptide.  After tetramer depletion, PBMC cultures were stimulated with 
NS3358-375 peptide (Figure 2.9A).  Because of variability in levels of proliferation, 
responses in the presence of each variant were normalized to WT alone; note the effect of 
dilution upon responsiveness at 25% (vol/vol). T cell responses in the restored presence 
of all variant-specific T cells were suppressed in a dose dependent manner. To control for 
nonspecific depletion and suppression, we used a CLIP-loaded tetramer, which resulted 
in no effect on the T cell response. Depletion of PBMC cultures with NS3358-375 tetramer 
and subsequent add-back of NS3358-375-specific T cells actually enhanced proliferation at 
lower volumes.  This result is not due to toxicity because the same concentration of 
tetramer (10µg/ml) added into culture along with the respective peptide(s) at 1µM 
resulted in no inhibition of T cell proliferation (Figure 2.9B).  We conclude from these 
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experiments that variant-tetramer-positive T cells are able to suppress T cell proliferation 
to wild type NS3358-375 in vitro. To our knowledge this is the first demonstration of what 
may be antigen-specific regulatory T cells. 
 
MHC Class II Tetramer Staining of NS3358-375-Specific CD4+T Cells 
 To extend our observation that variant-specific T cells are able to bind to cells that 
are specific for the cognate peptide in a somewhat larger cohort of subjects, we amplified 
CD4+ T cells specific for NS3358-375 peptide.  PBMC from HLA-DR15 subjects (Table 
2.1) were prelabeled with (0.5µM) CFSE and stimulated with NS3358-375 synthetic peptide 
for 7 days.  The CD4+ CFSElow cells were sorted, expanded with CD3/CD28 beads, and 
stained with tetramer following removal of beads.  All cultures were >99% CD4+ as 
determined by flow cytometry (data not shown).  Tropomyosin #20 (HLA-DR1/3) are 
CFSElow CD4+ T cells expanded in the same manner except that shrimp tropomyosin was 
substituted for NS3358-375 and served as an additional negative control (Figure 2.10, first 
column). Nonspecific tetramer (CLIP) –APC and –PE were also used as controls in each 
experiment (Figure 2.10). As might be expected, NS3358 and variant MHC class II 
tetramers stain PB3019, PH1127, and PH1079 CD4+ antigen-specific T cells all of which 
share or require the HLA-DR15 restriction element.  Thus, tetramers loaded with either 
cognate or variant peptides are likely to bind overlapping subsets of T cells found in 






 We demonstrate in vitro induction of regulatory T cells capable of suppressing 
antigen-specific T cell responses. We postulated that previously defined viral variants in 
a Th1 epitope could be responsible for the induction of Tregs based on the cytokine shift 
and attenuated T cell response (17). Further, chronically infected subjects exhibited 
significantly lower T cell responses in comparison to resolved subjects.  These attenuated 
T cell responses correlated with the induction of the Treg lineage-specific markers in 
proliferating T cells specific for rNS3.  
 Although Fuller et al. (33) identified and tracked HCV NS3 viral variants in MHC 
class II-restricted epitopes in an infected chimpanzees, similar to our previous work (20), 
but it was not clear if the viral-variants were able to affect the T cell response to cognate 
peptide. Our study demonstrated that viral variants attenuated T cell responses to cognate 
peptide and not unrelated peptide.   Further, the specific variant, S370P, induced Foxp3 in 
an antigen specific manner in a chronic HCV patient.  In an effort to generalize our 
finding from one chronic subject, we were able to detect variant-specific T cells in 
multiple HLA-matched subjects. The ability to detect the wild type positive T cells along 
with variant specific T cells suggests that the mechanism of Treg induction by naturally 
occurring epitope variant is likely not exclusive to one chronically infected individual, 
albeit the functional studies, though cumbersome, now need to be done in a larger cohort 
of chronic and resolved HCV patients.  
 Previous studies had found that depletion of CD4+CD25+ cells enhanced HCV-
specific T cell response to HCV antigens; however, these studies also described enhanced 
T cell response to control antigens from Epstein-Bar Virus (EBV), Cytomegalovirus 
 41 
(CMV), and influenza indicating that the depletion of this subset of cells is not specific 
for HCV (4, 34). Depletion of CD4+CD25+ cells restored PBMC proliferative responses 
to NS3358-375 to levels that matched or exceeded those in the nondepleted PBMC cultures 
that were preincubated with variant peptide.  An increase in the level of proliferation 
induced by variant K371E alone following CD4+CD25+ cell depletion implied a 
suppressive role for CD4+CD25+ Treg cells.  These results suggest that nonspecific 
depletion of Tregs enhanced T cell proliferation. 
 Compelling evidence for HCV-specific Tregs by Ebinuma et al. (35) identified 
CD4+CD25+ Foxp3+ MHC class II tetramer positive cells in peripheral blood of HCV 
patients.  Further, Heeg et al. (7) performed a longitudinal study using MHC class II 
tetramer staining to track HCV-specific CD4+ Foxp3+ T cells during the course of HCV 
infection in a cohort of patients.  Although Heeg’s study did not find a correlation 
between an increase in Foxp3 expression and viremia, they did observe an attenuated 
antigen-specific T cell proliferative response and lowered IFNγ secretion in MHC class II 
tetramer positive cells.  These studies did not identify viral variants arising in the epitopes 
analyzed, therefore giving no indication if viral variants could have an effect on the 
cognate T cell response (7, 35).   Depleting HCV-specific T cells that bind to MHC class 
II variant tetramers, we found an enhanced T cell proliferative response to NS3358-375 
peptide and a restoration of suppression when the variant-specific T cells were added 
back. Although the depletion of S370P tetramer positive cells did not significantly 
enhance the proliferative response over the nondepleted culture, the variant tetramer 
depletion results suggest that the avidity of the tetramers for NS3358-375- T cells are 
different, leading us to hypothesize that these variants could be acting as altered peptide 
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ligands. Consistent with this, K371E had a higher T cell response when CD4+CD25+ cells 
and K371E tetramer positive cells were removed indicating that this variant might affect 
yet a different subset of cells. Further, adding variant tetramer positive cells back into 
NS3358-375 stimulated cultures had a dose-dependent suppressive effect, suggestive of 
Tregs.  Taken together, our results suggest antigen-specific Tregs are responsible for 
suppression of an effector T cell response and we believe that a possible mechanism for 
this phenomenon is that Hepatitis C viral variants may act as APLs to induce Tregs.  
Previous (21, 36) and current work in our laboratory clearly demonstrates that viral 
variants are able to antagonize cloned T cells specific for NS3358-375.  Further, the variant 
peptides loaded onto MHC class II have different avidities for T cells that are specific for 
NS3358-375, which suggests that these variants are acting as naturally occurring altered 
peptide ligands (Chapter 4). 
 It has been observed that wild type HCV sequences remain stable in humans and 
chimpanzees even years into an ongoing infection (2, 31, 33, 37). We have shown that 
approximately 80% of the circulating virus has “wild type” 1A sequence (21, 31). 
Interestingly, the S370P variant was found in two isolates separated by 2 years, the 
variation has not impacted viral fitness negatively, yet its frequency seems not to have 
increased with time as might be expected with other escape models. Indeed, of all 
variants within the NS3358-375 epitope tested to date, none has lost the ability to bind the 
DR15 class II restriction element, which is contrary to a classic evasion escape model 
(38). The fact that HCV epitope variants seem to induce a functional unresponsiveness in 
peripheral T cells implies a radically different viral strategy as well host-related 
immunopathogenesis. HCV seems to have developed the ability to induce a specific 
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tolerance to itself by exploiting natural mechanisms that operate within the host. Our data 
suggest the hypothesis that viral mutation leads to APL that blunts specific helper T cell 
responses, which thereby attenuates the usual effector mechanisms requisite for antibody 
and killer T cell induction. 
 In conclusion, we have shown for the first time that variants of an HCV 
immunodominant epitope, which arose during chronic infection in a human, induced 
Foxp3 expression in an antigen specific manner and had a dose-dependent suppressive 
effect in vitro, perhaps reflective of regulatory T cells.  While the number of individuals 
studied to this point is small, we know that such variation occurs in other individuals and 
applies to the cytotoxic effector arm of the immune response as well (39); notably, this 
latter study was performed in an HLA-DR15-positive subject.  Therefore, our in vitro 
results imply that selective immune driven viral variants do not “escape” immune 
detection, similar to observations by Fuller et al. (33), but rather they avoid the 
consequences of immune recognition by inducing antigen-specific Tregs which in turn 
provide “immunological cover” for wild type viral sequences including those that contain 
the NS3358-375  epitope, which should otherwise be recognized, provide effective T cell 
help such that virus can be appropriately eliminated. Our results do not oppose other 
mechanisms for viral persistence, but may act in concert to subvert the adaptive immune 
response to HCV.  
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HCV and HLA types of chronic and resolved subjects used in this study.  All subjects’ 
PBMC were incubated with recombinant NS3 protein (rNS3) in a dose dependent manner 
using a proliferation assay to detect T cell responses. All subjects were screened for HCV 
RNA by quantitative PCR.  In the case of resolved subjects, in which they had no 
detectable viral load, a RIBA was performed to screen for HCV antibodies.  * Subjects 
used for T cell proliferation assay in Figure 2.1. 
 
Subject ID HCV status Genotype HLA- DR AB
*RLM 037 R - 1,15 +
*KML044 R - 9,15 +
*ZSS035 R - 1,15 +
*LEC028 R - 1,8 +
*KTJ010 R - 1,15 +
*BPB026 R - 3,15 +
*DRB012 R - 7,7 +
*JVP008 R - 15,15 +
JPZ061 R - 4,4 +
PH1127 R - 13,15 +
PH1079 R - 4,15 +
*AJG066 C 1A 1,8 ND
*KRW002 C 1A 8,14 ND
*MH065 C 1A 14,15 ND
*P.B3019 C 1A 15,7 ND
*NLM049 C 1A 11,13 ND
*CER014 C 1A 7,13 ND
*DRB051 C 1A 1,13 ND
*SSB007 C 1A 7,13 ND
RLW027 C 1A 4,15 ND
P.1022 NI - 8,10 -
P.1163 NI - 1,15 -
P.1078 NI - 9,13 -
P.1127 NI - 5,6 -
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Table 2.2.  CD4+ and CD8+ T cell responses to rNS3 and H3 antigens shown as 






Frequency of CD4+ and CD8+ T cells in CFSE labeled lymphocytes when stimulated with 
rNS3 and H3 at 10µg/ml for 7 days and analyzed by flow cytometry. On day 7, the cells 
were stained with CD4 and CD8. The proliferative response was determined by the 
medium for each subject.  Log10Δmax is the transformation of the T cell proliferation 
data for each subject and the respective antigen stimulation. 
  Medium              NS3                                 H3
Subject CD4 CD8 CD4 CD8 CD4 CD8
RLM 037R 0.97 1.5 7 7.1 4.4 1.5 4.91 0
KML044 R 0.29 0.5 4.1 11 4 0.3 0.63 0
ZSS035 R 0.6 1 4.1 2.7 4.2 3.7 1.85 4.1
LEC028 R 1.16 0.5 6 2.4 4 1.8 0.8 2
KTJ010 R 1.33 1.3 5 2.9 4 1.9 1.95 2.5
BPB026 R 0.4 0.3 1.6 1.1 3.2 0.4 0.22 2.7
DRB012 R 1.22 0.8 0.8 3.7 2.5 0.8 3.68 3.5
JVP008 R 0.4 0.5 2.6 4.1 3.2 0.8 0.47 3
JPZ061 R 1.34 1.8 1.1 1.4 3.3 1.2 1.3 0
AJG066 C 4.31 4.8 4.7 4.8 3.4 4.8 4.68 0
KRW002C 4.79 4.6 5.3 5.2 3.8 5.4 4.75 3.5
MH065 C 6.31 7.2 7 7.3 3.6 6.6 7.3 3.2
NLM049 C 1.84 4.5 2 14 3.5 0.2 0.84 3.05
CER014 C 0.68 0.3 1 0.8 4 0.7 0.33 3
SSB007 C 22.7 29 24 32 3.9 23 28.1 0
RLW027 C 0.16 0.4 0.3 2 4.2 0.2 0.84 3.8
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Table 2.3.  CD4+ and CD8+ CD127- expression. 
 
Frequency of CD4+ CD127- and CD8+ CD127- T cells in lymphocyte population when 
stimulated with rNS3 and H3 at 1mg/ml for 7 days and analyzed by flow cytometry. 
 
 
                                    CD127-
      Medium          NS3           H3
CD4 CD8 CD4 CD8 CD4 CD8
Subject
RLM 037 R 60.1 28 65.1 32.9 62.1 28.9
KML044 R 37.6 23.6 46.4 29.7 42.3 24.7
ZSS035 R 38.7 14.1 26.2 9.72 42.5 17.9
DOY041 R 40.7 20.3 42.7 18.1 46.1 24.3
LEC028 R 48.7 30.8 54.6 26.8 51.8 34.7
KTJ010 R 28.7 8.1 38.5 11 26.4 7.62
BPB026 R 32.8 22 37.1 9.75 33.1 10.5
DRB012 R 41 17.1 47.4 19.7 46.9 19
JVP008 R 35.9 15.4 42.4 19.7 34.2 16.2
JPZ061 R 38.6 18.7 44.6 27.9 45.5 27.3
AJG066 C 84 62.8 84 63.3 83.2 60.7
KRW002 C 62.8 54.7 63.9 57.9 64.1 57.5
MH065 C 51 54.7 44.7 45.5 51.7 56.8
NLM049 C 60.6 35.9 54.1 37.1 63.1 38.6
CER014 C 66.2 27.2 61 23.6 67 29.8
SSB007 C 59.2 33.3 52.9 23.8 61.1 35.9
RLW027 C 51.8 56.1 52.3 53.5 58.4 68
P.1022 NI 12.2 10.3 40.4 30.1 26.2 18.4
P.1163 NI 37.2 14 34.4 15.3 33.7 13.5
P.1078 NI 25.3 23.9 28.4 23.5 27 26.3
P.1127 NI 31 20.1 24.6 12.1 25.1 13.7
P.1031 NI 27.6 23.7 35.7 12.7 34.8 23.2
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Table 2.4. Frequency of CD4+ CD127- CFSElow Foxp3+ cells. 
 
Frequency of CD4+ CD127- CFSElow Foxp3+ cells in lymphocyte population when 
stimulated with rNS3 and H3 at 1mg/ml for days and analyzed by flow cytometry.. 
 
Subject
RLM 037 R 83.1 66 68.4
KML044 R 86.7 62 72.3
ZSS035 R 82.6 71.8 81.8
LEC028 R 79.3 84 85
KTJ010 R 47.4 57.7 41.9
BPB026 R 30.9 25 14.3
DRB012 R 61.4 46.4 46.4
JVP008 R 15.9 14.1 29.7
JPZ061 R 36.9 26.1 20.4
AJG066 C 52.3 66.6 57.2
KRW002 C 10.4 12.3 10.1
MH065 C 18.6 40.1 37.7
P.B3019 C 58.7 69.2 71.5
NLM049 C 16.5 16.9 31.7
CER014 C 18.6 40.1 37.7
DRB051 C 16.5 67 49.5
SSB007 C 12.3 17.3 10.9
RLW027 C 16.7 40.8 20
P.1022 NI 0 26.8 8.2
P.1163 NI 18.1 28 21
P.1078 NI 14.1 5.178 8.68
P.1070 NI 18.6 16.3 11.8
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Figure 2.1.  Resolved HCV subjects have a significantly higher T cell response to rNS3 
than chronic HCV subjects.  PBMC from both resolved subjects (gray circle) (n=8) and 
chronic (black triangle) (n=8) subjects (subjects used in Figure 2.1 are * in Table 2.1) 
were individually incubated with rNS3 (1µg/ml) and H3 (3µg/ml), H5 (3µg/ml), and 
PHA (2µg/ml) for 7 days. All subjects were screened in the same proliferation assay.  As 
described in the results, the algorithm: log10Δ max was used to transform the data (29). The 








































Figure  2.2. HCV subjects have an attenuated CD4+ T cell response to rNS3. HCV 
chronic subjects (black triangle) (n=7) (Table 2.2) had a significantly lower CD4 CFSElow 
response to rNS3 (1µg/ml) in comparison to resolved subjects (gray circle) (n=9) (Table 
2.2).  There was no difference in the H3 (1µg/ml) response between groups. The p<0.05* 
as determined by Student’s t-test. 
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Figure  2.3.  Higher frequency of Foxp3+ cells in chronic HCV subjects in comparison to 
resolved HCV subjects.  (A) Back Gating analysis of % Foxp3+ cells in CD4+ CD127- 
CFSElow cells.  PBMC were labeled with CFSE and then stimulated with either rNS3 
(1µg/ml) or H3 (1µg/ml) and incubated for 7 days.  The Fluorescence minus one (FMO) 
plus isotype control for Foxp3 antibody was used to determine the gate for Foxp3+ cells 
(upper panel). An example of PBMC stimulated with an antigen is shown in the lower 
panel.  (B) Chronic HCV patients (n=9) have a significantly higher percentage (*, p<0.05 
as determined by Student’s t-test) of CD4+ CD127- CFSElow Foxp3+ expressing cells in 
comparison to resolved HCV subjects (n=9), (Table 2.4). Δ=[Experimental - Medium].  
Noninfected subjects (n=5) were stimulated with the recombinant H3 antigen as a 

























Figure 2.4. PBMC proliferative responses to NS3358-375 peptide variants.  (A) HCV 
subject P.B3019 PBMC incubated for 3hrs. with peptide variants at 1µM, then with the 
addition of 1µM wild type peptide NS3358-375 where indicated.  On day 4, proliferating 
cells were labeled with 1 µCi 3H-TdR for the final 16 hrs. of incubation, and cells were 
harvested for measurement of 3H-TdR incorporation on day 5. Results are shown in mean 
counts per minute (CPM) +/- standard error of at least triplicate cultures.  *, p<0.05 as 




Figure 2.5.  Increased Foxp3 expression in an antigen specific manner by variant S370P 
stimulated PBMC from chronic P.B3019 (A) Representative flow plots of CFSElow 
Foxp3+ cells from lymphocytes that were CD4+ CD127- (gating scheme Figure 2.3A) 
stimulated with the indicated antigens at 1µM for 7 days.  Peptide added to PBMC 
cultures is listed above the plot and the percentages are the percent of CD4+CD127-
CFSElow cells. (B) Variant S370P (x= 81.8 ± SEM 5.7) stimulated PBMC significantly 
increases the expression of Foxp3 in CD4+CD127-CFSElow cells above the medium 





















Figure 2.6.  PBMC proliferative responses to NS3358-375 peptide variants and mixes with 
wild type peptide in cultures depleted of CD4+CD25+ Treg cells.  Subject 3019 total or 
Treg-depleted PBMC were stimulated with peptide variants and measured 3H-TdR-
uptake.  Results are mean counts of six wells each +/- SEM, representative of three 
independent experiments.  Gray bar, individual peptide; stripped bars, CD4+CD25+ Treg-
depleted PMBC.  *, p<0.05 as determined by Student’s t-test.  **, p<0.005. 
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Figure 2.7.  DRB1*1501 MHC class II variant and cognate tetramers are able to bind to 
CD4+ T cells from multiple patients.  PBMC from a noninfected (P1163), chronic 
(P.B3019), and resolved (JVP008) were individually stained with DR15 MHC class II 
tetramers (2µg/ml). P.1163, noninfected DR15 subject, was used as a control to test for 
nonspecific labeling of each DR15 tetramer (first column). DR15-CLIP –APC and –PE 




Figure 2.8.   Tetramer depletion of T cells specific for variant peptides restores T cell 
proliferative response to cognate NS3358-375. (A-C) Variant tetramer depleted listed at the 
top of the panels.  Tetramer depletion was done using PBMC from subject PB3019.  
PBMC incubated with variant peptide for 3 hrs. and then stimulated with WT peptide for 
7 days (Blue and red panel).   Black histogram is indicative of add back experiment, in 
which 10% represents approximately the same number of cells as normal mix population.  
Each experiment was done in triplicate, replicated 3 times for a total 9 data points. (D) 
HLA-DR15 CLIP tetramer depleted cells shown in yellow compared to PBMC from 




















Figure 2.9.  Tetramer positive cells suppress T cell proliferation in a dose dependent 
manner. P.B3019 PBMC were stained with pooled variants of H369R, S370P, and 
K371E (black), CLIP (light gray), or WT NS3358-375 (dark gray) and removed by bead 
depletion.  After tetramer depletion, the cultures were stimulated with NS3358-375 peptide. 
Tetramer positive cells were volumetrically added back into culture with P.B3019 
NS3358-375 stimulated PBMC. Data are representative of percent response to NS3358-375 
stimulated PBMC depleted with indicated tetramer(s) (WT alone) and set to 100%. 
Controls were CLIP (light gray) and NS3358-375 (dark gray).  (B) PB3019 PBMC cultures 
were stimulated with indicated peptide(s) with each tetramer added at 10µg/ml and 







Figure 2.9 continued 
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Figure 2.10.  MHC class II tetramers are able to stain NS3358-375 antigen-specific CD4+ T 
cells.  PBMC from PB3019, PH1127, and PH1079 were prestained with CFSE and 
stimulated with NS3358-375 synthetic peptide for 7 days.  The CFSElow cells were sorted 
and then stained with each tetramer.  The cells are >99% CD4+ as determined by flow 
cytometry (data not shown).  Trop#20 are CFSElow tropomyosin-specific CD4+ T cells 
expanded by the same procedure as NS3358-375.  Trop #20 was used to control for tetramer 
specificity (first column). Nonspecific tetramer (CLIP) was used for each experiment 
(bottom 2 panels). NS3358 and variant MHC class II tetramers stain PB3019, PH1127, and 







NATURALLY OCCURRING CD4+ T CELL EPITOPE VARIANTS 
 ACT AS ALTERED PEPTIDE LIGANDS LEADING  
TO IMPAIRED HELPER T CELL RESPONSES 







 Hepatitis C virus (HCV) has a high rate of replication and lacks RNA-
proofreading capabilities, thereby leading to variant or mutant viruses circulating within 
the host as quasispecies.  Previous work in our laboratory identified viral variants that 
emerged in a class-II immunodominant epitope NS3358-375 of the nonstructural-3 (NS3) 
protein region of HCV, the sequence of which is based on genotype 1A, the most 
prevalent genotype in the U.S. population.  Further work suggested that positive immune 
selection pressure was driving viral variation. Paradoxically, viral variants account for 
only a small percentage of the circulating virus in humans and chimpanzees, suggesting 
that passive evasion is not the only means of escape by HCV.  This observation suggests 
a unique pathogenesis for HCV as it persists in the host.  In the current study, we 
hypothesize that viral variants are acting as altered peptide ligands (APLs).  To test this 
hypothesis, we used cloned T cells specific for NS3358-375 peptide, which demonstrated 
attenuated T cell and IFNγ responses to individual variant peptides, when compared to 
the NS3358-375 stimulated T cell clones. Furthermore, such variants could act as APLs, 
based on their ability to antagonize the IFNγ proliferative responses of clones specific for 
NS3358-375. In addition, MHC class II tetramer staining demonstrated that variant MHC 
complexes were able to specifically bind to NS3358-375 T cell clones. Taken together, the 
results suggest that viral variants may act as APL to effectively blunt the T cell response 






 T cell activation occurs when a T cell receptor (TCR) binds to cognate or specific 
peptide bound to major histocompatibility complex (pMHC) molecules on the surface of 
antigen presenting cells (APCs) (1).  The engagement of the TCR to pMHC is necessary 
for the activation of CD4+ and CD8+ T cells, thereby leading to an effective adaptive 
immune response against an invading pathogen (2). Single amino acid substitution in the 
cognate peptide, termed altered peptide ligands (APLs), can elicit a gradient of effector 
function changes in a specific T cell (3). 
 The recognition of these segments of a pathogen or epitopes presented by the 
pMHC to T cells is critical for the clearance of viruses (4).  As in the case of Hepatitis C 
virus (HCV) infection, clearance of the virus has been found to be dependent upon the 
quality of the CD4+ T cell response in up to 30% of individuals infected (5-8). Mueller et 
al. (9) have detected virus-specific CD4+ T cells in chronic HCV patients, suggesting a 
novel mechanism of viral persistence (10-14). 
 Previous work in our laboratory identified viral variants that emerged in an MHC 
class-II immunodominant epitope NS3358-375 of the nonstructural-3 (NS3) protein region 
of HCV (15).  Further work suggested that positive immune selection pressure was 
driving viral variation (16). In contradiction to viral escape models, HCV variants 
account for only a small percentage of the circulating virus in humans and chimpanzees 
(17, 18). Also, HCV is able to modulate the immune response specifically towards viral 
persistence, indicating that HCV may be able to exploit a different mechanism in place of 
a more passive evasion strategy, leading to nondetection of the HCV pathogen by the 
immune system (16).  
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 One such mechanism that HCV may be able to exploit for persistence includes 
APLs, which have been observed within the hypervariable region 1 (19, 20), and in other 
pathogens, such as HBV (4, 21), HIV (22, 23) and plasmodium falciparium (24). Our 
previous studies identified and tracked viral variants arising in a single HCV chronic 
individual and further determined the effect these variants had on the in vitro immune 
response (15, 16, 18). Although HCV circulates in the host as a quasispecies, it appears 
that such variation does not lead to viral escape, but rather that some variants are able to 
suppress the immune response in an antigen-specific manner. 
 To test the hypothesis that viral variants could act as APLs, we used cloned T 
cells specific for the MHC class II epitope NS3358-375 peptide. The APL peptides alone 
had low T cell and cytokine responses in comparison to cognate peptide, all of which has 
been documented elsewhere (16). Prepulsing clones with variant peptides revealed that 
variants were able to antagonize proliferative and IFNγ responses to wild type NS3358-375 
peptide.  Further, MHC class II tetramers staining, loaded with variant peptides, are able 
to bind specifically to NS3358-375 T cell clones. Thus, viral epitope variants are able to 
blunt the responses of the very T cells that should help with the elimination of virus. Our 
results also help to explain observations that CD4+ T cells responses to HCV antigens 
seem attenuated or missing in chronically infected patients; they also bear on the findings 






Materials and Methods 
Blood Samples 
 These studies have been reviewed and approved by the University of Utah and the 
Medical College of Wisconsin Institutional Review Boards.  Isolation of lymphocytes 
and subsequent HLA typing was previously described (27). 
 
Synthetic Peptides 
 In vitro PBMC and T cell clones were stimulated with synthetic peptides 
representing one human leukocyte antigen DRB1*1501 restricted-epitope surrounding 
HCV NS3 amino acids 358-375 (aa 1384-1401 of the HCV polyprotein) as previously 
described (28, 29).  The three single amino acid variants were identified in a chronic 
HCV patient (P.B3019) (28, 29). Peptide sequences were as follows: wild type 358-375 
(NS3358-375), VIKGGRHLIFCHSKKKCD; variant H369R, VIKGGRHLIFCRSKKKCD; 
variant S370P, VIKGGRHLIFCHPKKKCD; variant K371E, 
VIKGGRHLIFCHSEKKCD. 
 
T Cell Proliferation Assay 
 To measure proliferative responses of PBMC and T cell clones following 
stimulation with wild type peptide NS3358-375 and variants peptides, cells were plated at 1 
x 105/ well in round-bottom 96 well plates and incubated at 37ºC, 5% CO2 at indicated 
times and peptide doses.  The cells were pulsed overnight with 1 µCi/well of titrated 
thymidine (3H-TdR) (Perkin Elmer, Waltham, Massachusetts) and harvested onto glass 
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fiber filters (Perkin Elmer) for measurement of radiolabel incorporation by scintillation 
counter (Perkin Elmer). 
 
T Cell Clones 
 Specific helper T cell clones, towards HCV NS3 peptide 358-375 (NS3358), were 
generated from a resolved DRB1*1501/1301 resolved hemophiliac individual (PH1127).  
PH1127 PBMC were re-suspended and plated into 96 well flat bottom plates (200µl/well) 
at 2 x 106 cells/ml.  Cells were stimulated with NS3358-375 at 5µM/ml at 37°C, 5% CO2 
incubator.  Cells were provided 10 U/ml rhIL-2 (BD bioscience).  On day 14, cells were 
tested for responsiveness to NS3358-375.  Functional cells were further subcloned by 
limiting dilution at cell densities of 10, 3, 1, and 0.3 cells/well in 96 flat bottom plates, 
which contained 105 irradiated (3000 rad) autologous PBMC.  T cells from 0.3cells/well 
were moved to 24 well plates and cultured with 10µM/ml NS3358-375 peptide and 10U/ml 
of rhIL-2 in complete media. Culture of PBMC and T cell clones were cultured in 
complete media:  RPMI 1640 tissue culture medium (BioWhittaker, Walkersville, ME) 
supplemented with 25 mM HEPES, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin, 1 mM sodium pyruvate, 5 µg/ml gentamycin (all from Mediatech Cellgro, 
Herndon, VA), 10 U/ml heparin sodium (Fisher Scientific, Pittsburgh, PA) and 10% pure 
human serum (Atlanta Biologicals, Lawrenceville, GA).  T cell clones were tested for 
responsiveness to NS3358-375 and variant peptides.  Cells were cultured in a 37ºC, 5% CO2 





 Cell culture supernatants IFNγ levels were determined by a commercial ELISA 
kit from Pharmingen, Inc. (San Diego, CA, USA) according to the manufacturer’s 
instructions.  Experimental values were determined by comparing the optical densities 
with a standard curve derived from recombinant IFNγ.  Negative controls consisted of 
background levels of APC cultured with T cell clones and complete media.  Each 
experiment was done in triplicate. 
 
Antagonism Assay 
 Antigen presenting cells (APCs) were prepulsed 2 hrs. with wild type at 1µM, 
washed (3x) in complete media + 10%PHS and irradiated at 300 Rad.  APCs were split (2 
x 105 cells/well) into 96 well trays contain variant peptides at indicated concentrations 
and T cells were added at 1 x 104 cells/well.  Cells were incubated at 37°C for 48 hrs.  
Then 100µl of supernatant was removed for ELISA screening and 3[H]-thymidine was 
added for 18 hrs. before harvesting and measuring 3[H]-thymidine incorporation. 
 
Anergy Assay 
 APCs were prepulsed for 3 hrs. with variant peptides at 1µM, washed, and 
irradiated (3000 rad).  The APCs were split into wells containing NS3358-375 peptide at 
0.1, 1, or 10µM concentrations.  T cells were subsequently added at 1 x 104 cells/well and 
incubated at 37°C for 48 hrs. 100µl of supernatant was saved for ELISA screening and 




 All tetramers were obtained from the NIH tetramer facility at Emory University. 
T cell clones were stained either with 358-375- Phycoerythrin (PE), or variant H369R-
Allophycocyanin (APC); variant S370P-APC; variant K371E –APC tetramers for 1hr at 
37°C.  7-AAD (BD bioscience), cell viability probe, CD4-pacific blue (BD bioscience), 
CD3-Amcyan (BD bioscience), CD8-FITC (eBioscience) were added for 15 min. at 4°C, 
washed with flow stain buffer (BD bioscience) and analyzed on a BD FACSCanto II. 
Negative controls consisted of staining cells with nonspecific peptide, CLIP-DR15 
tetramer, labeled with either –PE label or –APC respectively.  Further, T cell clone 
HA306-318 was stained with each tetramer (data not shown). Results were compared using 
Student’s t-test and considered significant if the p<0.05.  Flow cytometry data analysis 
was performed using Flow Jo software (Tree Star). 
 
Results 
Epitope Variants Have an Attenuated T Cell Proliferative Response 
 To determine if naturally occurring epitope variants are acting as APL and thus 
antagonizing or anergizing potential helper T cell responses, we used T cell clones 
specific for NS3358-375.  The T cell clones specific for NS3358-375 were derived from a 
resolved HCV patient PH1127 (HLA-DR15) that recognizes a previously characterized 
immunodominant NS3358-375 epitope (Figure 3.1A, B) (30, 31).  Furthermore, previous 
work has demonstrated that the variants are able to bind to HLA-DR15 molecules (16, 
32).  T cell clones derived from PH1127 are labeled as T.358 and these T cell clones have 
an attenuated T cell proliferative and IFNγ response to the variant peptides (Figure 3.1C, 
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D). The inability of variant peptides to activate T cell proliferation and IFNγ secretion 
when incubated with variant peptides led us to investigate if these variants were 
antagonizing the cognate T cell response. 
 
Characterization of Variant Peptides as Antagonists 
 To determine if the variants could serve as antagonists, cells were prepulsed with 
1µM NS3358-375 (open circle) and co-cultured in a dose-dependent manner with variant 
peptides (Figure 3.2).  The variants effectively antagonize the T cell response in both the 
polyclonal and T cell clone assays in a dose-dependent manner (Figure 3.2). Furthermore, 
the IFNγ cytokine levels are attenuated in a similar fashion as the proliferative response 
(Figure 3.2B,D).  Taken together, the viral variants act as an antagonist due to the lack of 
both proliferative and IFNγ response, when both variant and cognate peptides are present. 
 To assess if the variant peptides are anergizing the cognate T cell response, APCs 
were prepulsed with 1µM variant peptides for 3 hrs., washed, irradiated, and cultured 
with T cell clones and cognate NS3358-375 (Figure 3.3).  H369R blunts both T cell 
proliferative and IFNγ response, but variants S370P and K371E act as partial-antagonists 
(Figure 3.3).  These results suggest that one variant is able to anergize T cells and 
variants S370P and K371E act as partial-antagonists. 
 
Viral Variants Engage NS3358-375 T Cell Clones 
 To establish viral variants capacity to bind to NS3358-375 T cells, T cell clones 
were stained with MHC class II tetramers (Figure 3.4).  Tetramers loaded with each 
individual peptide were used to stain T358.3.  All three variant tetramers were able to 
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bind to T358.3 clones (Figure 3.4, red histogram).  The ability of these MHC class II 
tetramers to bind to the same T cell clones as the NS3358-375 suggests that these variants 




 We demonstrate that variant epitopes modulate in vitro immune responses to the 
cognate peptide. Our results suggest that naturally occurring variants within a protective 
immunodominant epitope may act as APLs, leading to changes in the quality of T cell 
responses, which could allow for viral persistence. 
 This viral persistence seems relevant considering that HCV is able to modulate 
the immune response in an antigen-specific manner. This was shown by the fact that the 
variants were able to attenuate the response to NS3358-375 in antagonism assays.  Each 
variant showed unique effects on the wild type response that ranged from anergy by 
H369R to partial-antagonism by S370P and K371E. By comparison, work by Scotta et al. 
(20) studied the effects of hypervariable region 1 variants in a CD4+ T cell epitope and 
found that the antagonists were able to induce apoptosis.  We observed no evidence of 
induced programmed cell death, as Annexin-V/PI staining in polyclonal assays showed 
no difference in cultures treated with variants alone or in combination with wild type 
NS3358-375 (Chapter 4).  Interestingly, our lab had shown that variant S370P was found to 
be stable in a chronic HCV patient for over 2 years, consistent with selection and fixation 
of this variant (15). In the current study, S370P was still able to induce a proliferative and 
IFNγ response, albeit at lower levels than the wild type peptide, and are able to bind 
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specifically to T cell clones specific for cognate peptide.  It seems that S370P is able to 
act on the in vitro response to HCV through varied suppressive mechanisms (33, 34).  
One such mechanism of suppression is Tregs, in that, preincubating PBMC with S370P 
increases phenotypic markers for Tregs (Chapter 2).  Expanding these findings to a larger 
cohort of subjects, the Treg markers are found at significantly higher levels in PBMC 
from both resolved and chronically infected patients; we were able to show the antigen-
specific induction of Tregs (Chapter 2). 
 A defining feature of APLs is the ability of the antagonist peptide, coupled to 
pMHC, to bind to the TCR. In the current study, we used MHC class II tetramers to 
determine whether variant peptides coupled to MHC were able to bind to T cell clones 
specific for NS3358-375 and possess the same TCR.  The variants were able to bind to the T 
cell clones, suggesting that this has an effect on the biological outcome of the T cell.  
These results do not clearly demonstrate the kinetics of the pMHC-TCR and is currently 
being investigated.  Although tetramer staining addresses the ability of the variants to 
bind to the same TCR as the wild type tetramer, further investigation needs to be 
performed to determine if markers of antagonism are upregulated, such as the 
phosphatase SHP-1 (35). 
 Using cloned T cells specific for the MHC class II epitope NS3358-375 peptide and 
previously identified naturally occurring APLs within a protective immunodominant 
epitope, suggests that changes in TCR activation may be used by HCV to deviate or blunt 
an HCV-specific T cell response (16).  These results provide an explanation for the 
attenuated or missing CD4+ T cells in chronically infected patients (25, 26). Although 
these results suggest that HCV is exploiting TCR signaling for viral persistence, further 
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investigation into APLs effect on the differentiation of these antigen-specific CD4+ T 
cells is necessary to understand HCV pathogenesis. 
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Figure 3.1.  Viral variants H369R, S370P, and K371E have an attenuated T cell 
proliferative and IFNγ response in both polyclonal and T cell clone assays, when 
compared to cognate NS3358-375 stimulated cells. A,C.  Cognate peptide has a dose-
dependent T cell response and the variant peptides have an attenuated T cell response.  
Medium alone was used as a negative control. Results are shown in mean counts per 
minute (CPM) +/- standard error of triplicate cultures.  B,D. Corresponding IFNγ 
response for polyclonal and T cell clones.   Results are shown pg/ml- medium +/- 
standard error of triplicate cultures.  D. Medium was subtracted from the experimental for 
each sample. PBMC from PH1127 were cultured for 5 days and T cell clones for 72 hrs. 
at indicated peptide concentrations. *, p<0.05 as determined by student’s t-test.  D.  


























Figure 3.2.  Variant peptides act as antagonists.  A.  PBMC were incubated with 1µM 
NS3358-375 for 3 hrs. and then washed. NS3358-375 variant peptides were added to the 
culture at indicated doses and incubated for 5 days.  B. Supernatants were collected at 48 
hrs. from the cell culture and IFNγ levels were measured. C,D.  Antigen-presenting cells 
were prepulsed with NS3358-375 peptide for 3 hrs., washed, irradiated and cultured with T 
cell clones with variant peptide for 72 hrs. The dotted line with open circle represents 
proliferation by NS3358-375 peptide prepulse alone.  D.  The supernatants from T358 were 















Figure 3.2 continued 
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Figure 3.3.  H369R variant anergizes NS3358-375 specific T cells. A-B.  PBMC were 
prepulsed with indicated variant peptide and subsequently stimulated with NS3358-375 
peptide in a dose dependent manner.  C-D.  APC cells were incubated with variant 
peptide for 3 hrs., washed, irradiated and added to T cells with varying concentration of 
the cognate peptide.  B,D. Supernatants were collected at 48 hrs. and the IFNγ levels 

















Figure 3.4.  Variant MHC class II tetramers bind to NS3358 T cell clones. Histograms of 
MHC class II tetramer (red) staining.  CLIP loaded DR15 tetramer was used as a control 
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 A wide breadth of work has demonstrated a correlation between Hepatitis C Virus 
(HCV) persistence and an increase in regulatory T cells (Tregs).  The relationship 
suggests that HCV could modulate CD4+ T cells in an antigen-specific manner, thereby 
leading to a symbiotic relationship between the host and the virus.  The mechanism 
responsible for the increase of Tregs is unknown. One possibility for the up regulation of 
Tregs is through naturally occurring viral variants. Viral variants have been found to act 
as altered peptide ligands (APLs) in HCV infection, leading to modulated T cell 
responses. Further, we have demonstrated that one viral variant was able to induce Treg 
phenotypic markers.  Taken together, we hypothesized that one possible mechanism of 
induction of Tregs is through viral variants antagonizing HCV-specific T cells.  We 
performed in vitro assays using two subjects that respond to the wild type peptide.  Our 
results indicate that both the wild type and variant peptides are necessary for the 
suppression of a T cell response. Using MHC class II tetramers to compare the avidity of 
the wild type to variant, the variant tetramer had a lower avidity for the antigen-specific 
CD4+ T cells.  Further, one viral variant, S370P, induced an up regulation of Foxp3 in 
MHC class II tetramer wild type positive cells.  Lastly, confocal microscopy portrays 
variant and wild type tetramers binding to the same T cell.  These results demonstrate that 
a stable viral variant in a chronic HCV subject is able to induce Tregs in multiple 
individuals that are able to respond to an HCV-specific CD4+ T cell epitope.    
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Introduction 
 Hepatitis C Virus (HCV) is a positive-stranded RNA virus that circulates the host 
as a heterogeneous population.  The most frequently represented genome is referred to as 
the wild type sequence; the viral variants arising in the viral genome are called 
quasispecies (1).  The majority of circulating viruses in chronic HCV subjects appear to 
be the wild type population (2-4). The role of these quasispecies or viral variants in HCV 
pathogenesis can range from simple escape to deviation of the immune response, possibly 
leading to viral persistence (5, 6). In opposition to simple escape models, HCV variants 
have been found to account for only a small percentage of the circulating virus in humans 
and chimpanzees (3, 4, 6, 7). This paradox of wild type viral genomes persisting in the 
presence of T cells implies that there may be another level of immuno-regulation that is 
modulated by HCV (8-12). 
 The recognition of HCV epitopes or segments of the virus presented by the 
peptide-major histocompatibility complex (pMHC) to T cells is necessary for HCV 
clearance (13-16). Previous studies have demonstrated that naturally occurring viral 
variants arising in CD4+  “helper” T cell epitopes are able to modulate T cell signaling (6, 
17).  These results suggest one of the mechanisms that HCV may be able to exploit for 
persistence is altered peptide ligands (APLs) (17). APLs are capable of modulating the T 
cell response by having an amino acid substitution in the cognate peptide (18).  A number 
of pathogens that have been shown to exploit APLs for persistence including HCV (17, 
19), HBV (20, 21), HIV (22, 23), and plasmodium falciparium (24).  Previous work in 
our laboratory identified naturally occurring viral variants arising in an immunodominant 
CD4+ T cell epitope (6).  One viral variant, S370P, was found to be stable for over 2 
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years, suggesting “selection and fixation” of this HCV viral isolate, which indicates a role 
for this variant in HCV pathogenesis (6, 25). Recently, we have found that viral variant 
S370P is able induce Tregs to suppress the antiviral T cell response in an antigen-specific 
manner (Chapter 2).    
 Tregs can be classified into two groups.  One kind are Tregs induced in the 
periphery have been termed inducible Tregs, defined by secretion of IL-10, TGFβ, and 
IL-4 and natural Tregs (nTregs), which are selected for in the thymus and are 
characterized by the extra cellular surface markers CD4+ CD25+ (26, 27).  Although there 
are other extra cellular surface markers suggestive of Tregs, the most accepted marker is 
the expression of the transcription factor Forkhead Box P3 (Foxp3) (28).  The expression 
of Foxp3 is critical in the development of Tregs (29-33). An increase in Treg markers has 
been shown in cohorts of chronic HCV subjects when compared to resolved and 
noninfected individuals, suggesting that HCV is inducing Tregs for viral persistence (3, 
34-39). 
 Recent work has demonstrated that HCV is able to exploit naturally occurring 
viral variants to modulate CD4+ T cell responses (17, 19).  Taken together, we 
hypothesized that one possible mechanism of induction of Tregs is through viral variants 
antagonizing HCV antigen-specific T cells.  We performed in vitro assays using two 
HCV subjects that respond to the wild type peptide.  Both the wild type and variant 
peptide are necessary for the suppression of a T cell response.  Using MHC class II 
tetramers, we tested the avidity of the variant tetramer to antigen-specific CD4+ T cells 
and found the avidity was different in comparison to the wild type tetramer.  Further, one 
viral variant, S370P, induced an up regulation of Foxp3 in MHC class II tetramer wild 
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type positive cells. Lastly, fluorescent microscopy clearly shows that both the variant and 
the wild type tetramers stain the same T cell.  These results demonstrate that a stable viral 
variant in a chronic HCV subject is able to induce Tregs in multiple individuals that are 
able to respond to an HCV-specific CD4+ T cell epitope. 
 
Materials and Methods 
Lymphocytes 
 These studies have been reviewed and approved by University of Utah and 
Medical College of Wisconsin Institutional Review Boards.  Peripheral blood 
mononuclear cells (PBMC) were isolated isolation over Lymphocyte Separation Medium 
(GE-Healthcare) and preserved in liquid nitrogen, as previously described (40). Human 
leukocyte antigen (HLA) class II typing had been performed on each patient, as 
previously described.   PB3019 is DRB1*0701/1501 and PH1127 is DRB1*1501/1301.  
PB3019 is a chronic HCV subjects infected with genotype 1a, as previously described 
(2). Hemophiliac individual PH1127 is a resolved HCV subject with detectable antibody 
for HCV (5). 
 
Synthetic Peptides 
 Synthetic peptides representing one DRB1*1501 restricted-epitope surrounding 
HCV NS3 amino acids 358-375 (aa 1384-1401 of the HCV polyprotein) were 
synthesized as previously described (5, 41).  The three single amino acid variants were 
identified in a chronic HCV patient (P.B3019) (5, 41). Peptide sequences were as 
follows: wild type 358-375 (NS3358-375), VIKGGRHLIFCHSKKKCD; variant H369R, 
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VIKGGRHLIFCRSKKKCD; variant S370P, VIKGGRHLIFCHPKKKCD; variant 
K371E, VIKGGRHLIFCHSEKKCD. 
 
Cell Culture and Media 
 Culture of PBMC was in RPMI 1640 tissue culture medium (BioWhittaker, 
Walkersville, ME) supplemented with 25 mM HEPES, 2 mM L-glutamine, 100 U/ml 
penicillin, 100 µg/ml streptomycin, 1 mM sodium pyruvate, 5 µg/ml gentamycin (all 
from Mediatech Cellgro, Herndon, VA), 10 U/ml heparin sodium (Fisher Scientific, 
Pittsburgh, PA) and 10% human serum (Atlanta Biologicals, Lawrenceville, GA).  Cells 
were cultured in a 37ºC, 5% CO2 incubator. 
 
T cell Proliferation Assay 
 To measure proliferative responses of PBMC following stimulation with indicated 
peptides, cells were plated at indicated cell concentrations in round-bottom 96 well plates 
(Costar) and incubated at 37ºC, 5% CO2 at indicated times and peptide doses.  The cells 
were pulsed for the last 16-18 hrs. of incubation with 1 µCi/well of titrated thymidine 
(3H-TdR) (Perkin Elmer, Waltham, Massachusetts) and harvested onto glass fiber filters 
(Perkin Elmer) for measurement of radiolabel incorporation by scintillation counter 
(Perkin Elmer). 
 
CD4+ T Cell Line 
 Antigen-specific NS3358-375 CD4+ CFSE T cells were derived from PH1127 and 
PB3019.  PBMC from PH1127 and PB3018 were labeled with 0.5µM 
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Carboxyfluorescein succinimidyl ester (CFSE) and stimulated with NS3358-375 synthetic 
peptide.  On day 7, the cells were stained with CD4-APC (Invitrogen, Carlsbad, CA) and 
cell sorted at the University of Utah cell sorting core facility.  The CD4+ T cells were 
sorted by either CFSEhigh (non-proliferating) or CFSElow (proliferating).  The cells were 
washed and expanded by CD3/CD28 dynabeads (Invitrogen) with 10U/ml of human rIL-
2 ((BD Pharmingen, San Diego, CA).  Prior to testing the CFSE cells for responsiveness 
to NS3358-375, the CD3/CD28 beads were removed, washed, and rested for 3 days. CD4+ 
CFSE cells (2 x 104 cells/well) were stimulated with increasing concentrations of NS3358-
375 peptide by a mixture of chronic and resolved HLA-DR15 APCs treated with 10µg/ml 
Mitomycin C (Sigma Aldrich, USA) at 1 x 105 cells/well for 3 hrs. prior to incubation. 
 
Antagonism Assay 
 APCs were prepulsed for 2 hrs. with indicated peptide concentration, washed (3x) 
in complete media + 10%PHS and then treated with Mitomycin C at 5µg/ml for 1hr and 
washed (3x) in complete media + 10% PHS.  APCs were split (1 x 105 cells/well) into 96 
well trays contain variant peptides at indicated concentrations and T cells were added at 2 
x 104 cells/well.  Cells were incubated at 37°C for 48 hrs.  Then 100µl of supernatant was 
removed for ELISA screening and 3[H]-thymidine was added for 16-18 hrs. before 
harvesting and measuring 3[H]-thymidine incorporation. 
 
Tetramer Staining 
 T cells were stained with tetramers (NIH tetramer facility at Emory University) 
358-375- Phycoerythrin (PE), or variant H369R-Allophycocyanin (APC); variant S370P-
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APC; variant K371E –APC tetramers for 1hr at 37°C.  7-AAD (BD bioscience), CD4-
pacific blue (BD bioscience), CD3-Amcyan (BD bioscience), CD8-FITC (eBioscience) 
were added for 15 min. at 4°C, washed with flow stain buffer (BD bioscience) and 
analyzed on a BD FACSCanto II (BD Biosciences). Negative controls consisted of 
staining cells with nonspecific peptide, CLIP-DR15 tetramer, labeled with either –PE 
label or –APC respectively.  Further, CD4+ CFSElow T cells specific for Tropomyosin 
were stained with each tetramer. Flow cytometry data analysis was performed using Flow 
Jo software (Tree Star). 
 
Foxp3 Staining 
 Cultures were then stained with 358-375- Phycoerythrin (PE) tetramer for 1hr, 
CD4-Pacific Blue, CD3-Amcyan, CD25-APC, and 7-AAD were added for the last 20 
min. at 4˚C and then washed 2x with stain buffer (BD Pharmingen).  Using eBioscience 
Foxp3 staining kit, the cells were fixed and permeabilized for 1hr at 4˚C, washed 2x in 
permeabilization buffer.  Normal rat serum was added (2µl/100µl) for 15 min. and then 
stained with Foxp3-FITC (eBioscience) for 1hr at 4˚C, washed 2x with stain buffer and 
analyzed on a BD FACS Canto II.  To account for fluorescence spill over and nonspecific 
staining, we performed fluorescence-minus-one (FMO) with isotype control.  These FMO 
controls contain all of the antibody conjugates used in the experiment except Foxp3-
FITC, with the addition of FITC- isotype control.  This was performed for each culture 





 Images were obtained at the University of Utah School of Medicine Cell Imaging 
Facility.  The CD4+ T cells were fixed in BD cytofix for 1hr at 4°C.  The cells were 
washed 1x with BD pharmingen’s Stain Buffer [Dulbecco’s Phosphate Buffered Saline 
(DPBS), pH 7.4, 0.2% Bovine Serum Albumin, containing 0.09% Sodium azide].  1 x 105 
cells/50µl CD4+ T cells were stained with 10µg/ml of MHC class II tetramers for 2 hrs. at 
4°C, washed 2x in Stain Buffer, and imaged.  Fluorescent images were obtained using a 
Nikon AR1 system with a 60x oil objective.  The Emissions wavelength (EmW) and 
Excitation wavelength (ExW) for -PE (EmW/ ExW) was 595/561.2 and –APC (EmW/ 
ExW) was 700/635.8. 
 
Results 
Both NS3358 and Variant S370P Peptides are Necessary for T Cell Suppression 
 Previous work demonstrated that variant S370P was able to attenuate the T cell 
responses to NS3358 peptide.  To determine if viral variant S370P was able to suppress a 
T cell response to a nonspecific antigen, PBMC from PB3019 were preincubated with 
either an individual peptide or both peptides when the cells were stimulated with 2µg/ml 
PHA (Figure 4.1).  PBMC preincubated for 3 hrs. with either NS3358 or S370P had no 
effect on the T cell response to PHA, whereas PBMC preincubated with S370P (1µM) for 
3 hrs. with the addition of NS3358 (1µM) and PHA (2µg/ml) suppressed the T cell 
response (Figure 4.1, black bar).  These results suggest that the suppressive phenotype 
was dependent on the presence of both the viral variant and cognate peptide. 
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Creation of a NS3358 Antigen-Specific T Cell Line 
 To amplify NS3358 antigen-specific CD4+ T cells from PH1127 (resolved) and 
PB3019 (chronic) HCV subjects, PBMC were prelabeled with CFSE and subsequently 
cell-sorted by CD4+ CFSEhigh/low (Figure 4.2A-B).  After expanding the sorted CD4+ T 
cells (>99%, data not shown) with CD3/CD28 beads, the CD4+ T cells (2 x 104) were 
tested for responsiveness to NS3358 peptide by using APCs (1 x 106 cells/ml) from DR15-
subjects that were treated with Mit-C, after the cells were rested for three days (Figure 
4.2C-D).  The CFSElow cells are specific for NS3358 peptide in a dose-dependent manner 
and the CFSEhigh T cells had no T cell response (Figure 4.2C-D). The development of 
NS3358-375-specific CD4+ T cell lines led us to investigate if variant S370P was able to 
antagonize these NS3358-specific T cells. 
 
Variant S370P Acts as an Antagonist 
 To establish variant S370P as an antagonist, CD4+ CFSElow T cells were 
stimulated with either NS3358 or S370P peptides in a dose-dependent manner (Figure 
4.3A).  Variant S370P had an attenuated T cell response, which is consistent with 
antagonism.  When the APCs were prepulsed with variant S370P (1µM) and the cells 
were cultured in an increasing concentration of NS3358 peptide, S370P was able to 
attenuate the T cell response in an antigen-specific manner (Figure 4.3B). 
 
Variant Tetramers Have Lower Avidities in Comparison to NS3358 Tetramer 
 To determine if the viral variants could bind to the TCR of NS3358 CD4+ T cells, 
MHC class II tetramer dilution assays were performed (Figure 4.4).  Nonspecific CLIP-
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tetramer at 12µg/ml was performed for each experiment as a control and tetramer staining 
dilutions were performed by a dilution factor of three for each tetramer (Figure 4.4A).  
The frequency of tetramer positive cells is similar between H369R and NS3358 but S370P 
and K371E variants have a lower frequency (Figure 4.4B).  The median fluorescence 
intensity (MFI) had a similar trend as the frequency of tetramer positive cells, in that wild 
type and H369R are similar and variants S370P and K371E had a four fold lower MFI 
(Figure 4.5C).  The CD4+ T cell line was stained with each variant and NS3358 tetramer, 
thereby competing each variant against the wild type tetramer.  Variant H369R has a 
much higher avidity at 2µg/ml then NS3358 tetramer, indicating that variant is anergizing 
these T cells (Table 2.1).  Taken together, the variant peptides have different avidities for 
the same TCR, which suggests that the variants are able to modulate NS3358-375-specific 
CD4+ T cells. 
 
Variant S370P Induces Foxp3 in NS3358 CD4+ T Cells 
 To address if variant S370P was antagonizing NS3358 CD4+ T cells to differentiate 
into Tregs, Foxp3 cell frequency was determined in NS3358 MHC class II tetramer 
positive cells.   Using NS3358 CD4+ T cell lines derived from both PH1127 and PB3019, 
stimulated with either the individual peptides or both S370P and NS3358 peptides at 1µM 
were cultured with Mit-C treated APCs and peptides for 72 hrs.  Subsequently, the cells 
were stained with the NS3358 tetramer in combination with the indicated fluorochromes 
(Figure 4.5).  CLIP-DRB1*1501-PE tetramer was used as a control and fluorescence 
minus one (FMO); the isotype control for Foxp3 antibody was also used for each 
experiment (Figure 4.5).  The histograms represent the 7-AAD- CD8- CD3+ CD4+ 
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NS3358-DRB1*1501+ cells that are Foxp3+ (Figure 4.5).  The S370P stimulated T cells 
have a higher frequency of Foxp3 (Figure 4.5, red histogram).  Taken together, S370P 
antagonizes the CD4 T cell lines to differentiate in Tregs.  To our knowledge, this is the 
first demonstration of a naturally occurring variant inducing TH1-cells to differentiate into 
a Treg. 
 
MHC II S370P Tetramer Stains the Same Cell as MHC II NS3358 Tetramer  
 To solidify if variant S370P was binding to the same T cells as the wild type 
tetramer, we performed MHC class II tetramer staining on NS3358-specific CD4+ T cells.  
NS3358 and S370P tetramers were added to the indicated CD4+ T cell line in tandem 
(Figure 4.6). The NS3358 tetramer appears to stain the majority of T cells but the S370P 
tetramer does not individually stain the cells.  Instead the variant co-localizes with the 
NS3358 tetramer (Figure 4. 6). CD4+ Tropomyosin specific T cells were used as a control 
for the tetramers (Figure 4.6, last column).  The CD4+ Tropomyosin-specific T cells were 
stained at the same time and with the same tetramers as PH1127 and PB3019 T cells 
(Figure 4.6, third row).  These results show that variant S370P is able to bind to the same 




 We demonstrate that naturally occurring APLs induce antigen-specific CD4+ T 
cells to differentiate into Tregs in vitro. Furthermore, the wild type and variant peptide is 
necessary for the suppression of a T cell response.  These results indicate that a stable 
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viral variant, arising in an epitope that is conducive to viral clearance, was able to alter 
the T cell differentiation of a TH1 CD4+ T cell to a Treg cell. 
 The maintenance of an abundant population of wild type HCV sequences has 
been observed in infected humans and chimpanzees even years into an ongoing infection 
(2-4, 42). Viral variation accounts for < 20% of the circulating viral sequence in the 
chronically infected person used in this study (2, 6). From these identified viral variants 
arising in the NS3358-375 epitope, there was a subset of variants able to attenuate the T cell 
proliferative responses to the cognate peptide (2). Interestingly, the viral variant S70P, 
previously shown to induce Treg phenotypic markers, was unable to suppress mitogen 
activated T cells, but if S370P was presented in conjunction with the cognate peptide, the 
T cell response to the mitogen was inhibited.  Taken together, the presence of the wild 
type in conjunction with the variant is necessary for the suppressive effect of these T 
cells, but the induction is antigen-specific. 
 The quality of CD4+ T cell response has been found to be critical in the clearance 
of HCV, but the detection and expansion of CD4+ T cells derived from chronically 
infected HCV subjects has been hampered by a lack of detection and proliferation (7, 13-
16). To circumvent the issue of CD4+ T cell expansion from a chronic HCV subject, we 
developed an NS3358-375-specific CD4+ T cell line. Variant S370P was able to antagonize 
NS3358-375-specific CD4+ T cells. In support of these results, work by Frasca et al. (17) 
has shown that APLs were able to antagonize the HVR1-specific T cell clones and 
suppress the T cell response when both the APL and cognate peptides were presented on 
the same APCs. Further work by Scotta et al. (19) ascertained that certain APLs were 
able to induce cell death, but the viral variants used in the current study did not induce 
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programmed cell death in comparison to the wild type NS3358-375 peptide (Figure 4.7 and 
4.8).  Recently, Mueller et al. (43) had detected virus-specific CD4+ T cells in chronic 
HCV patients, indicating the presence of HCV-specific CD4+ T cells in chronic 
individuals, indicating that naturally occurring APLs could be exploiting other 
mechanisms for persistence, such as T cell anergy or rendering the T cells unresponsive. 
  A defining feature of APLs is the ability of the antagonist peptide coupled to 
MHC (pMHC) to bind to the TCR. Tetramer avidity tests using MHC class II tetramers 
clearly demonstrate a difference in avidity between the wild type and variants with the 
exception of H369R. It appears that H369R has a similar avidity to the wild type 
tetramer.  Functional data indicate that the H369R variant is blunting the NS3358-375- T 
cell proliferation, which is indicative of T cell anergy but needs further investigation.  
Similar results to the tetramer avidity tests were found when each variant was added into 
culture with the wild type tetramer, in that S370P and K371E were double positive, but 
H369R had a higher avidity for the T cells (Figures 4.9- 4.11).  Also, these tetramer 
competition assays indicate that both the variant and the wild type tetramer are able to 
bind to the same T cell, thereby providing further evidence that both the variant and 
cognate peptides are working in-concert on the same T cell.  These naturally occurring 
APLs within a protective immunodominant epitope could possibly have differential 
effects on TCR activation and may be used by HCV to deviate or blunt an HCV-specific 
T cell response.  
 We have previously demonstrated that variant S370P induced Foxp3 expression 
in an antigen-specific manner and had a dose-dependent suppressive effect in vitro, 
reflective of Tregs (Chapter 2). Chronic HCV infected individuals have an increase in 
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Treg markers when compared to noninfected individuals (3, 34-39). This induction of 
Tregs in chronic HCV subjects appears to be antigen-specific due to the identification of 
Foxp3+ MHC class II tetramer positive cells from PBMC of HCV patients (44).  Heeg et 
al. (39) has tracked MHC class II tetramer positive cells that were HCV-specific CD4+, 
and expressed Foxp3+ T cells during the course of HCV infection in a cohort of patients.  
Further, they observed an attenuated antigen-specific T cell proliferative response and 
lowered IFNγ secretion in MHC class II tetramer positive cells (39). Also, MacDonald et 
al. (3) had identified inducible Tregs that recognized the same HCV core epitopes as TH1 
IFNγ-secreting T cells.  Even more compelling, evidence suggesting that Tregs are 
induced, possibly leading to viral persistence, was demonstrated in acute infection (45).  
These studies support HCV-induction of Tregs but do not explore the mechanism of 
induction of Tregs (39, 44). In our study, naturally occurring APLs alter the TCR 
signaling as suggested by our T cell proliferation data and these variants induce a Tregs 
phenotype.  Taken together, we determined that variant S370P was able to induce Foxp3 
expression in NS3358-375-MHC class II tetramers positive cells that are antigen-specific in 
two individuals.  This mechanism of Treg induction is HCV antigen-specific, and the 
phenomenon of Treg induction is not exclusive to one HCV chronic subject. 
 The most widely accepted Treg marker, Foxp3, is dependent on IL-10 signaling in 
CD4+ T cells (46).  Further, it has been demonstrated that IL-10 serum levels are 
significantly higher in chronic vs resolved HCV subjects, thereby providing an 
environment that is conducive to Treg differentiation and maintenance (3).  Although the 
source of the endogenous IL-10 has been found higher in the serum of chronic subjects, 
the cell type(s) responsible for the IL-10 secretion has not been clearly defined and needs 
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further investigation. Similarly, the viral-variant S370P was able to activate and maintain 
Foxp3 expression in comparison to the NS3358-375 peptide when in the presence of IL-10, 
whether produced endogenously in a chronic patient or provided exogenously to cells in a 
resolved subject (data not shown). The suppressive nature of IL-10 is nonspecific and 
presumably the immune system in chronic HCV subjects would be dampened; but in a 
cohort of subjects tested for T cell responses to influenza antigens, we found the T cell 
response was not significantly lower when compared to resolved HCV subjects (Chapter 
2).   
 Although the cohort of chronic HCV subjects had an intact memory T cell 
response, the chronic subject used in this study had an attenuated T cell response to 
influenza antigens, suggesting that there immune system was dampened in this one 
chronic HCV subject and this could be due to being chronically infected.  To circumvent 
the issue of IL-10 in our assay system, we used a mixture of chronic and resolved APCs.  
Herein, we show that Foxp3 is induced in an antigen-specific manner. 
 In conclusion, we demonstrate that naturally occurring viral variants are acting as 
APLs that work synergistically with the cognate peptide to cause antigen-specific 
differentiation in T cells. Such T cells are thence able to suppress nonspecific T cell 
responses reminiscent of Tregs. Thus, by tolerating mutation in specific T cell epitopes, 
HCV may be able to shift the immune response towards conditions that are conducive to 
viral persistence. Further work should determine if priming strong CD4+ T cell responses 
could provide protective immunity against HCV or lead to viral elimination in 
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Table 4.1.  Variant and NS3358 tetramer competition for PB3019low and PH1127low CD4+ 
T cells.  H369R variant had the highest avidity in comparison to NS3358 tetramer.  Each 
variant tetramer was added to CD4+ CFSElow NS3358 antigen-specific T cells at the same 




Figure 4.1.  Both cognate and variant peptides are necessary for the suppression of T cell 
proliferation.  P.B3019 PBMC was stimulated with individual peptides (light gray bars).  
The PBMC were preincubated with either S370P or NS3358 3 hrs. prior to the addition of 
PHA (1µg/ml) (dark gray bars).  PBMC were preincubated with S370P for 3 hrs. and 
NS3358 and PHA (1µg/ml) were added (black bar). 3H-thymidine was added at day 6 and 
3H-thymidine uptake was measured 16-18 hrs. later. 
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Figure 4.2.  CD4+ CFSElow T cells stimulated with NS3358 peptide are antigen specific T 
cells.  A-B.  PBMC from PB3019 and PH1127 were prelabeled with CFSE.  The cells 
were stimulated with 1µM of NS3358 peptide for 7 days. Cells were sorted by 
proliferating cells (low) and nonproliferating cells (high).  Cells were expanded with 
CD3/CD28 beads and rIL-2 (10U/ml).  Prior to stimulation with cognate peptide, the 
beads were removed and rested for 3 days.  C-D.  APCs (1 x 105 cells/well) were added 
with increasing concentrations of NS3358 peptide.  CD4+ T cells were added at 2 x 104 
cells/well and incubated for 72 hrs. 3H-thymidine was added to the cultures 16-18 hrs. 








Figure 4.2 continued 
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Figure 4.3.  Variant S370P antagonizes NS3358 antigen-specific T cells.  A.  T cell 
proliferation assay with individual peptides added in a dose dependent manner to CD4+ 
CFSElow T cells (2 x 104 cells/well) from both PH1127 and PB3019 patients with 1 x 105 
APCs/well and incubated for 72 hrs.  B.  APCs (1 x 105 cells/well) were prepulsed with 
S370P for 3 hrs., washed, treated with Mitomycin C and added to CFSElow T cells (2 x 
104 cells/well) for 72 hrs. in the presence of NS3358 peptide. 3H-thymidine was added to 
the cultures 16-18 hrs. prior to measuring 3H-thymidine uptake.  Assays were performed 










Figure 4.4.  NS3358 and variant tetramers have different TCR avidities.  A.  
Representative flow plots of NS3358- MHC class II staining of CD4+ CFSElow T cells was 
performed in decreasing concentrations of individual tetramers.  B. Frequency of tetramer 
positive cells for each tetramer.   C.  Median Fluorescence Intensity (MFI) for each 








Figure 4.4 continued 
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Figure 4.5.  Viral variant S370P is able to induce Foxp3 expression in an antigen specific 
manner.  CD4+ CFSElow T cells from PH1127 and PB3019 were stimulated with either 
individual peptides (1µM/ml) or prepulsed with S370P (1µM) and cultured for 72 hrs.  
The cells were stained with NS3358 MHC class II tetramer.  Tetramer positive cells were 
stained for Foxp3 (histogram).  Gating for MHC class II tetramer staining was 
determined by control tetramer CLIP-DRB1*1501 tetramer.    Dark gray histogram is 
NS3358 stimulated T cells and red histogram is the S370P stimulated CFSElow cells that 









Figure 4.5 continued 
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Figure 4.6.  NS3358 and S370P MHC class II tetramers are able to bind to CD4+ NS3358 T 
cells. The fluorescent images were all taken using identical confocal settings including 
laser power, emission filters, pinhole, and scan speed. The cells were stained with both 
NS3358-PE (green) and S370P-APC (red) MHC class II tetramers at 10µg/ml. PB3019low 
and PH1127low CD4+ T cells are specific for NS3358 (rows one and two).  CD4+ 
Tropomyosin specific T cells were used as a control (third row).  The inset (column 3, 
panel 2) has been multiplied by three to reveal the level of background for comparison to 
the experimental panels shown in the same column. 
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Figure 4.9.  H369R and NS3358 tetramer competition assay.  Both H369R and NS3358 
tetramers (10µg/ml) were added to the indicated CD4+ T cell lines at the same time.  
Patient #20 tropomyosin was used as a control for the tetramers and CLIP loaded 





Figure 4.10.  S370P and NS3358 tetramer competition assay. Both S370P and NS3358 
tetramers (10µg/ml) were added to the indicated CD4+ T cell lines at the same time.  
Patient #20 tropomyosin was used as a control for the tetramers and CLIP loaded 







Figure 4.11.  K371E and NS3358 tetramer competition assay.  Both K371E and NS3358 
tetramers were (10µg/ml) added to the indicated CD4+ T cell lines at the same time.  
Patient #20 tropomyosin was used as a control for the tetramers and CLIP loaded 








 This dissertation describes the methodology and potential influence of the in vitro 
induction of Tregs capable of suppressing protective antigen-specific T cell responses to 
an immunodominant epitope of HCV. I hypothesized that previously defined viral 
variants in this TH1 immunodominant epitope could be responsible for the induction of 
Tregs, a postulation based upon the cytokine shift and attenuated T cell response (1). 
These findings offer new insight into the occurrence of chronically infected HCV 
subjects exhibiting significantly lower T cell responses in comparison to resolved 
subjects.  These attenuated T cell responses correlate with the induction of Treg lineage-
specific markers in proliferating T cells specific for rNS3.   Additional investigation of 
this process suggests that naturally occurring variants induce Tregs and may act as APLs, 
leading to changes in the quality of the T cell responses. The latter part of this 
dissertation blends the two previously described concepts by demonstrating that naturally 
occurring APLs serve as the mechanism of Treg induction, leading us to term this 
mechanism of viral-specific induction of Tregs as “convergent suppression” (Figure 1.5). 
 Naturally occurring escape variants of HCV have been identified but very little 
work has been done to characterize the possible impact that viral variants could have on 
T cell responses to the wild type HCV epitope.  The work performed in this dissertation 
demonstrates that viral variants attenuate T cell responses to wild type peptide, but not 
unrelated peptide, thereby suggesting that APLs serve as a mechanism by which HCV 
may be able to deviate the immune response and persist.   Furthermore, the specific 
variant, S370P, induced Foxp3 in an antigen-specific manner in a chronic HCV patient.  
In an effort to generalize our finding from one chronic subject, we were able to detect 
variant-specific T cells in multiple HLA-matched chronic and resolved subjects. The 
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ability to detect the wild type specific T cells, along with variant-specific T cells, 
suggests that this mechanism of Treg induction by variants is not exclusive to one chronic 
HCV subject.  Future studies into mechanisms of Treg induction would use more HLA-
matched individuals, both chronic and resolved, in functional assays to further 
demonstrate APL induction of Tregs as described in this dissertation. 
 Compelling evidence for the existence of HCV-specific Tregs in vivo was 
presented by Ebinuma et al. (2) who identified CD4+ CD25+ Foxp3+ MHC class II 
tetramer positive T cells in peripheral blood of HCV patients, supporting our results 
obtained from one patient.  Furthermore, Heeg et al. (3) performed a longitudinal study 
using MHC class II tetramer staining to track HCV-specific CD4+ Foxp3+ T cells during 
the course of HCV infection in a cohort of patients.  Although Heeg’s (3) study did not 
find a correlation between an increase in Foxp3 expression and viremia, they did observe 
an attenuated antigen-specific T cell proliferative response and decreased IFNγ secretion 
in MHC class II tetramer positive T cells.  These studies did not identify viral variants 
arising in the epitopes analyzed, thereby giving no indication whether viral variants could 
have an effect on the wild type T cell response (2, 3).  By depleting HCV-specific T cells 
that bound to MHC class II tetramers specific for the individual variants, we found an 
enhanced T cell proliferative response to the NS3358-375 peptide and a restoration of 
suppression when the variant-specific T cells were added back, suggestive of Tregs. 
 Consistent with the concept of variants acting as antagonists and leading to a 
suppressed T cell response, the T cell response was higher when CD4+ CD25+ T cells and 
T cells specific for variant K371E were removed, indicating that this variant might affect 
yet a different subset of T cells. Furthermore, adding pooled variant tetramer positive T 
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cells back into NS3358-375-stimulated cultures had a dose-dependent suppressive effect, 
suggestive of Tregs.  Combining these results suggests that antigen-specific Tregs are 
responsible for suppression of an effector T cell response.  These studies did not address 
if the variants are able to induce a subpopulation of CD4+ T cells and/or if these variants 
are causing the wild type-specific T cells to differentiate into Tregs, which needs further 
investigation. The second part of this dissertation demonstrates that these viral variants 
are able to antagonize clonal T cells specific for NS3358-375, and that these variants have 
different avidities, possibly modulating the T cell activation, leading to the induction of 
Treg phenotype.  Further evidence for antigen-specific induction of Tregs by MacDonald 
et al. (4) demonstrates that inducible Tregs are activated in the same HCV core-specific T 
cell clones, thereby providing supporting evidence that the antigen-specific induction of 
Tregs is not a phenomenon isolated to a singular chronic HCV subject or to these 
particular NS3 viral variants. 
 The conundrum is that the wild type genome is the dominant species circulating 
infected host (4-7). Interestingly, the viral variant S370P, previously shown to induce 
Treg phenotypic markers, was unable to suppress mitogen activated T cells when added 
alone, but if S370P was presented in conjunction with the wild type peptide; the T cell 
response to the mitogen was inhibited.  These findings indicate that the presence of the 
wild type peptide in conjunction with the variant peptide is necessary for the suppressive 
effect of these T cells, but the induction is antigen-specific, thus suggesting that the 
maintenance of the wild type genome is necessary for suppression of the immune 
response.   
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 Another mechanism that HCV can exploit for deviation of the immune response is 
APLs.  In order for a viral variant to be considered an APL, the variant must be able to 
bind to the same TCR as the wild type or immunogenic peptide and have a lower potency 
in comparison to wild type peptide-stimulated T cells (Figure 1.2). In this dissertation, 
MHC class II tetramers were used to determine whether variants coupled to MHC were 
able to bind to T cell clones expressing a TCR specific for NS3358-375.  The variants were 
able to bind to the wild type-specific T cell clones, suggesting that this has an effect on 
the biological outcome of the T cell.  In Chapter 4, tetramer avidity tests using MHC 
class II tetramers clearly demonstrate a difference in avidity between wild type and 
variant tetramer staining, with the exception of the H369R variant. This finding implies 
that the H369R variant tetramer has a similar or higher avidity when compared to the 
wild type tetramer.  Functional data suggest that the H369R variant is blunting the 
NS3358-375-specific T cell proliferation, which is indicative of T cell anergy, but this 
blunting/ anergy phenomenon requires further investigation. If the addition of IL-2 to 
PBMC cultures stimulated with both the H369R and wild type peptides causes a 
restoration of T cell proliferation to the wild type peptide, then the H369R variant is 
anergizing the T cells.  Further, tetramer competition assays were used to detect both the 
variant and wild type tetramers binding to the same T cell, thereby providing more 
evidence that both the variant and wild type peptides are working in-concert on the same 
T cell.  These naturally occurring APLs within an immunodominant epitope could 
possibly have differential effects on T cell activation and may be used by HCV to deviate 
or blunt an HCV-specific T cell response.  
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 Further work testing if these variants deviate the T cell response demonstrates 
variant S370P inducing Foxp3 expression in an antigen-specific manner in polyclonal in 
vitro assays, and likewise variant S370P has a dose-dependent suppressive effect in vitro, 
reflective of Tregs. As previously noted, chronic HCV-infected individuals have an 
increase in Treg markers when compared to noninfected individuals (3, 4, 8-12).  These 
studies support HCV induction of Tregs but do not explore the mechanism of induction 
of Tregs (2, 3). In this dissertation, naturally occurring APLs alter the TCR signaling, as 
suggested by our T cell proliferation data, and these variants induce a Tregs phenotype.  
In combining these findings, we determined that variant S370P was able to induce Foxp3 
expression in NS3358-375-MHC class II tetramer positive cells that are antigen-specific in 
two individuals.  We also determined that this mechanism of Treg induction is HCV 
antigen-specific, suggesting that this phenomenon of Treg induction is not exclusive to 
one HCV chronic subject.  This is the first demonstration that APLs are able to induce 
Tregs, therefore defining how HCV is able to maintain a wild type genome even in the 
presence of an intact immune system. 
 
T Cell Signaling Induced by Viral Variants 
 Although these results suggest that HCV is exploiting TCR signaling for viral 
persistence, further investigation into APL’s effect on the differentiation of these antigen-
specific CD4+ T cells is necessary to understand HCV pathogenesis.   Also, examining 
the role of downstream signaling molecules would solidify the conclusion that these viral 
variants are able to either antagonize or anergize these antigen-specific T cells. In this 
aspect, the tetramer staining addresses the ability of the variant tetramers to bind to the 
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same TCR as the wild type tetramer on the same T cell, but further investigation needs to 
be performed to determine if markers of antagonism, such as protein tyrosine 
phosphatase (SHP-1) or zeta-chain-associated protein kinase 70 (ZAP-70) 
phosphorylation, are up regulated.  Such information would further clarify if these 
variants are acting as APLs (13). Studies have demonstrated that SHP-1 is a cytosolic 
protein tyrosine phosphatase that has been shown to negatively regulate T cell activation 
(14), and that ZAP-70 is a protein tyrosine kinase that plays a crucial role in T cell 
signaling (15).  Although the wild type’s presence is necessary for the variants to have a 
suppressive effect, this dissertation does not address whether or not these two antigens 
need to be present on the same APC.  Our microscopy data demonstrates the variant and 
wild type tetramers co-localize which suggests that they need to be presented on the same 
APC.  This determination can be accomplished by prepulsing the APCs with either 
individual peptides and added into culture with a T cell clone or prepulse the APCs with 
both the wild type and variant peptides, so as to test the effect that these antigens have on 
T cell proliferation.  Furthermore, screening for these T cell proteins would give an 
indication as to whether or not these variants are antagonizing or anergizing specific T 
cells. 
 
The Role of IL-10 in the Induction of Tregs 
 An important question that arises when studying CD4+ T cells is the impact that 
the extra-cellular milieu has on the fate of these T cells. One mechanism by which Tregs 
mediate suppression is through the secretion of IL-10 (16).  Stimulating PBMC from a 
chronic subject with the S370P peptide increases the median fluorescence intensity of 
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CD4+ IL-10+ T cells, indicative of IL-10 secretion (data not shown). However, the 
addition of an anti-IL-10 antibody to cultures did not significantly restore the 
proliferative capacity of T the cells (data not shown).  This finding suggests that 
suppression by Tregs requires contact, a finding that supports numerous other studies 
demonstrating Treg suppression through contact-mediated mechanisms (10, 17).  
Although our results do not define a single mechanism of suppression, these findings 
suggest that secretion of IL-10 by Tregs could be important for the maintenance of the 
antigen-specific Tregs (18).  For example, a recent study by Murai et al. (18) in a murine 
colitis model showed that IL-10 was essential for the maintenance of Foxp3 expression 
and suppressive function of Tregs.  Therefore the presence of IL-10 should be necessary 
for the maintenance of Foxp3 in our in vitro model system.  The viral variant S370P was 
able to activate and maintain Foxp3 expression in comparison to the NS3358-375 peptide 
when in the presence of IL-10, whether the IL-10 produced endogenously in a chronic 
patient or provided exogenously to PBMC in a resolved subject.  Therefore, Foxp3 could 
be induced in an antigen-specific manner, and the maintenance of Foxp3 expression was 
dependent on IL-10 (Figure 5.1). 
 The most widely accepted Treg marker, Foxp3, is dependent on IL-10 signaling in 
CD4+ T cells (18).  Furthermore, it has been demonstrated that IL-10 serum levels are 
significantly higher in chronic patients in comparison to resolved HCV subjects, 
providing an environment that is conducive to Treg differentiation and maintenance (4).  
Although the level of endogenous IL-10 has been found to be high in the serum, the cell 
type(s) responsible for the IL-10 secretion has not been clearly defined and needs further 
investigation. The suppressive nature of IL-10 is nonspecific, and presumably the 
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immune system in chronic HCV subjects would be dampened by this suppressive 
cytokine. 
 Results from this dissertation indicate that Foxp3 is induced in an antigen-specific 
manner while previous work has demonstrated that the maintenance of Foxp3 expression 
is dependent on IL-10. To circumvent the issue of IL-10 in our assay system, we used a 
mixture of chronic and resolved APCs. Further clarification of this issue would be to the 
effect of this immunodominant epitope when added into the suppressive milieu of a 
chronically infected HCV patient.  Preliminary data (Figure 5.1) suggest that when this 
wild type epitope is delivered into culture with high levels of IL-10, Treg phenotypic 
markers are not increased.  This information leads us to hypothesize that this epitope is a 
plausible candidate for a vaccine for use in individuals who were unable to initially clear 
the virus.  Performing studies that use infected, resolved, and noninfected APCs to test 
the impact of the extracellular milieu on antigen-specific T cells give a “snap-shot” of 
what could happen in vivo when these viral antigens are presented to T cells in the 
context of an infection and the potential impact that the extracellular milieu has on T cell 
signaling. 
 
Alternative Therapy for HCV Clearance 
 Although the goal of these experiments was to define in vitro correlates of HCV 
pathogenesis leading to a better understanding as to how vaccines could be used to prime 
the immune system, so that one could clear the virus, the results of these studies indicate 
that there are alternative approaches to clearing the virus other than using a vaccine.  One 
such alternative to vaccination is to transplant an individual’s T cells back into the 
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chronically infected patient after selecting HCV-specific CD4+ T cells. In this scenario, 
HCV-specific T cells that drive viral clearance would be added back into chronically 
infected patients. Our work and that of others have characterized epitopes that are 
conducive for viral clearance and work in this dissertation clearly describes a technique 
for selecting, expanding, and characterized antigen-specific CD4+ TH1 cells.  The premise 
of this approach would be to identify CD4+ TH1 cells in a chronically infected individual, 
use CFSE-labeled PBMC from this individual stimulated with the TH1 epitopes by 
peptide stimulation and sort the epitope-specific CD4+ TH1 cells.  These CD4+ T cells 
would then be cultured with CD3/CD28 beads leading to nonspecific expansion of these 
T cells.  The antigen-specific T cells could then be adoptively transferred back into these 
chronically infected individuals in large numbers, driving the immune system towards 
viral clearance by CD4+ TH1 T cells, and possibly leading to viral clearance in a 
chronically infected patient. 
 In conclusion, the work presented in this dissertation shows that naturally 
occurring viral variants are acting as APLs that work synergistically with the wild type 
peptides to differentiate T cells, in an antigen-specific manner, as well as suppress T cell 
responses nonspecifically a mechanism which we have termed “convergent suppression” 
(Figure 5.2).  This information reveals that HCV may be able to shift the immune 
response towards viral persistence suggesting that priming the immune system with a 
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Figure 5.1.  Foxp3 expression is induced in an antigen-specific manner with the addition 
of IL-10.  (A) Histogram of Foxp3+ cells in CD4+ CD127- CFSElow lymphocyte 
population, stimulated with indicated peptides, and cultured in 2ng/ml of rhIL-10 (gating 
scheme Fig.3A).  (B) PBMC from PH1127 were cultured under normal conditions (gray 
bars) or with rIL-10 (2ng/ml) (black bars) and PBMC were stimulated with 1µM of 
synthetic peptide for 7 days and analyzed by flow cytometry. Under normal conditions (-
rIL-10), Foxp3 is transiently expressed in proliferating CD4+ CD127- T cells but S370P 
stimulated cells with rIL-10 have a significantly higher percentage of Foxp3+ cells in 
comparison NS3358-375-stimulated cells. The normal and rIL-10 were run in tandem (n=2) 
and the data were normalized to medium. **, P<0.005. The standard deviation is shown.  










Figure 5.2.  Model of convergent suppression in HCV infection.  If the wild type peptide 
(black) is presented to the CD4+ T cell prior to the variant variant peptide (red), this could 
lead to viral clearance.  If the viral variant (red) is presented to the wild type-specific 
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